EP3911319A1 - Dérivés d'imidazole fusionnés substitués et procédés de traitement de la drépanocytose et de complications associées - Google Patents

Dérivés d'imidazole fusionnés substitués et procédés de traitement de la drépanocytose et de complications associées

Info

Publication number
EP3911319A1
EP3911319A1 EP20741695.9A EP20741695A EP3911319A1 EP 3911319 A1 EP3911319 A1 EP 3911319A1 EP 20741695 A EP20741695 A EP 20741695A EP 3911319 A1 EP3911319 A1 EP 3911319A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
optionally substituted
compound according
halogen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20741695.9A
Other languages
German (de)
English (en)
Other versions
EP3911319A4 (fr
Inventor
Otis Clinton Attucks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
vTv Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by vTv Therapeutics LLC filed Critical vTv Therapeutics LLC
Publication of EP3911319A1 publication Critical patent/EP3911319A1/fr
Publication of EP3911319A4 publication Critical patent/EP3911319A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention provides methods of treating sickle ceh disease and related complications using compounds of Formula (I) and pharmaceutical compositions thereof either alone or in combination with other active agents.
  • the present invention also provides compounds and pharmaceutical compositions.
  • Sickle cell disease is a life-threatening monogenic disorder.
  • SCD is a severe hemoglobinopathy that produces multisystem complications due to the expression of abnormal sickle hemoglobin (HbS).
  • HbS sickle hemoglobin
  • SCA sickle cell anemia
  • HbSS also referred to as HbSS or SS disease or hemoglobin S
  • SCD in which there is homozygosity for the mutation that causes HbS.
  • the more rare types of SCD in which there is heterozygosity (one copy of the mutation that causes HbS and one copy for another abnormal hemoglobin allele) for the mutation include sickle-hemoglobin C (HbSC), sickle 6 + thalassemia (HbS/6 + ) and sickle 60
  • HbS/6° thalassemia
  • Sickle cell disease arise from a point mutation that causes erythrocyte deformation or sickle-shaped erythrocytes. Sickled- shaped erythrocytes are associated with clinical manifestations of SCD, such as anemia, recurrent painful vaso-occlusive episodes, infections, acute chest syndrome, pulmonary hypertension, stroke, priapism, osteonecrosis, renal insufficiency, leg ulcers, retinopathies, and cardiac disease.
  • SCD Sickle cell disease
  • SCD arises from a single point mutation (GAG>GTG) in codon 6 of the HBB globin gene.
  • the deoxygenated venous circulation causes a process of self-assembly (polymerization) that generates the sickled hemoglobin molecule (HbS) and damages the membrane and cytoskeleton of the erythrocyte.
  • HbS sickled hemoglobin molecule
  • the HbS repetitively enter into sickling and unsickhng cycles incrementally increasing the damage to the erythrocyte membrane (Ischemia-reperfusion (IR) injury) resulting in irreversibly sickle-shaped erythrocytes.
  • IR Ischemia-reperfusion
  • these rigid blood cells are unable to deform as they pass through narrow capillaries, leading to vessel occlusion and ischemia.
  • the actual anemia of the illness is caused by hemolysis, the destruction of the red cells, caused by their misshapes.
  • CRP C-reactive protein
  • oxidative stress contributes to hemolysis, inactivation of nitric oxide (NO), and erythrocyte, leukocyte and platelet adhesive properties.
  • NO nitric oxide
  • Heme oxygenase- 1 (HO- 1) and interleukin 10 (IL-10) are characteristically found to be increased in SCO patients in an attempt to counteract the induced inflammation.
  • HO- 1 breaks down heme released during hemolysis thereby limiting oxidative stress and inflammation, while IL- 10 limits the production of the pro- inflammatory cytokines.
  • Sickled erythrocytes stimulates leukocyte recruitment: ensuing the
  • leukocytes are recruited to the activated endothelium of the venous circulation where it forms adhesive interactions with the activated endothelium and sickled erythrocytes, leading to a reduced blood flow and eventually vaso-occlusion.
  • SCO platelets show increased surface expressions of selectin P (SELP), activated am, 6a (GPIIbllla) and higher concentrations of the platelet activation markers. In healthy individuals, platelet adhesion is inhibited by the selectin P (SELP), activated am, 6a (GPIIbllla) and higher concentrations of the platelet activation markers. In healthy individuals, platelet adhesion is inhibited by the selectin P (SELP), activated am, 6a (GPIIbllla) and higher concentrations of the platelet activation markers. In healthy individuals, platelet adhesion is inhibited by the
  • HU Hydroxyurea
  • HbF fetal hemoglobin
  • HU improved clinical symptoms by reducing pain and vaso- occlusive crises, acute chest syndrome, transfusion requirements, and hospitalization
  • SCO patients treated with HU have demonstrated side effects such as inducing DNA damage, reducing sperm counts and producing iron nitrosyl Hb.
  • PCT Publication No. WO 2011/103018 (“WO ⁇ 18”) describes substituted fused imidazole derivatives that upregulate expression of HMOX1 in vitro.
  • PCT Publication No. WO 2012/094580 (“WO’580”) describes various compounds that modulate cellular oxidative stress including fused imidazole derivatives having a structure similar to or the same as compounds disclosed in WO '018.
  • the present invention is directed to methods and compositions associated with treatment of one or more blood disorders.
  • the blood disorder is SCO
  • one or more other blood disorders may be treated with the present invention: a bleeding disorder (including clotting disorders, hypercoagulability, hemophilia, or von Willebrand disease, for example), platelet disorder (essential or primary thrombocythemia or thrombocytopenia, for example), and/or hemophilia or anemia may be treated, for example.
  • a bleeding disorder including clotting disorders, hypercoagulability, hemophilia, or von Willebrand disease, for example
  • platelet disorder essential or primary thrombocythemia or thrombocytopenia, for example
  • hemophilia or anemia may be treated, for example.
  • there are methods and compositions for treatment and/or prevention of sickle cell disease which may be referred to as sickle-cell anaemia (or anemia; SCA) or drepanocytosis).
  • Mammalian and/or non-human mammals or cell lines may be used as sickle cell models.
  • the individual treated with methods and/or compositions of the invention may be experiencing vaso- occlusive crisis, acute chest crisis, painful chest syndrome that may or may not require hospitalization, in specific cases.
  • the individual may be experiencing or may experience negative side effects of a drug, such as a drug that directly or indirectly results in increased coagulation and/or increased inflammation; in specific embodiments, the drug is HU.
  • a compound of the invention is administered alone.
  • a compound of the invention is administered with one or more other drugs (some of which may or may not induce HbF production) for the treatment of SCO.
  • a compound of the invention may be administered in combination with HU for the treatment of SCO.
  • a compound of the invention may be administered in
  • Nrf2 activator such as a fumarate ester (MMF or DMF) and bardoxolone methyl.
  • the individual treated may be known to have SCO, is suspected of or at risk for having SCO.
  • an individual is diagnosed with sickle cell disease prior to receiving the inventive treatment.
  • the present invention is also directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof and to pharmaceutical compositions comprising Formula (I) and pharmaceutically acceptable salts thereof, and methods of making thereof.
  • Figure IE comprises Western Blots showing the level of induction of HbF following treatment of KU812 cells with various concentrations (0, 0.5, 2.5, 5, 10, and 20 mM) of Compounds 73, 134, 473, and 236. Hydroxyurea (HU) and hemin were used as HbF induction positive controls, and 6-actin was used as a protein loading control.
  • Hydroxyurea (HU) and hemin were used as HbF induction positive controls, and 6-actin was used as a protein loading control.
  • Figure 2 shows HbF protein expression levels of KU812 cells obtained by FACs and analyzed as the mean concentration of HbF per cell measured by mean fluorescence intensity (MFI).
  • Figure 3 A comprises Western Blots showing the level of induction of HbF and HbS when sickle erythroid progenitor cells were treated with Compound 473 (0.5 and 2.5 mM) for 48 hours. Hydroxyurea (HU) and hemin were used as HbF induction positive controls, and b-actin was used as a protein loading control.
  • Hydroxyurea (HU) and hemin were used as HbF induction positive controls, and b-actin was used as a protein loading control.
  • Figure 3B shows the percent of HbF positive cells (F-cells) when sickle erythroid progenitor cells were treated with Compound 473 (0.5 and 2.5 mM) for 48 hours and analyzed by flow cytometry. Hydroxyurea (HU) and hemin were used as HbF induction positive controls.
  • Figure 4A contains images of sickle erythroid progenitor cells after culturing for 10 days, treating with Compound 473 for 48 hours at concentrations of 0.5 pM and 2.5 pM or with hemin (about 50 pM) or with hydroxyurea (HU) (about 100 pM), and then subjecting the cells to hypoxia conditions (1% O2 and 5% CO2).
  • Figure 4B shows the percent of sickled cells when sickle erythroid progenitor cells were cultured for 10 days and then treated with Compound 473 for 48 hours at concentrations of 0.5 pM and 2.5 pM or with hemin (about 50 pM) or with
  • alkyl refers to a straight or branched chain saturated hydrocarbon having one to ten carbon atoms, which may be optionally substituted, as herein further described, with multiple degrees of substitution being allowed.
  • alkyl as used herein include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, isobutyl, n-butyl, sec-butyl, tert-butyl, isopentyl, n- pentyl, neopentyl, n-hexyl, and 2-ethylhexyl.
  • Ci- 6 alkyl represents an alkyl chain having from 1 to 6 carbon atoms and, for example, includes, but is not limited to, methyl, ethyl, n- propyl, isopropyl, isobutyl, n-butyl, sec-butyl, tert-butyl, isopentyl, n-pentyl, neopentyl, and n-hexyl.
  • alkylene refers to a straight or branched chain divalent saturated hydrocarbon radical having from one to ten carbon atoms, which may be optionally substituted as herein further described, with multiple degrees of substitution being allowed.
  • alkylene as used herein include, but are not limited to, methylene, ethylene, n-propylene, 1-methylethylene, 2- methylethylene, dimethylmethylene, n-butylene, 1- methyl- n-propylene, and 2- methyl-n-propylene.
  • Ci-4alkylene represents an alkylene chain having from 1 to 4 carbons atoms, and, for example, includes, but is not limited to, methylene, ethylene, n-propylene, 1-methylethylene, 2-methylethylene,
  • cycloalkyl refers to a saturated, three- to ten- membered, cyclic hydrocarbon ring, which may be optionally substituted as herein further described, with multiple degrees of substitution being allowed.
  • Such “cycloalkyl” groups are monocyclic, bicyclic, or tricyclic. Examples of
  • cycloalkyl groups as used herein include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and adamantyl.
  • C x.y cycloalkyl refers to a cycloalkyl group, as herein defined, containing from x to y, inclusive, carbon atoms. Similar terminology will apply for other terms and ranges as well.
  • C3- 10 cycloalkyl represents a cycloalkyl group having from 3 to 10 carbons as described above, and for example, includes, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and adamantyl.
  • heterocycle refers to an optionally substituted mono- or polycyclic saturated ring system containing one or more heteroatoms.
  • Such“hetercycle” or“heterocyclyl” groups may be optionally substituted as herein further described, with multiple degrees of substitution being allowed.
  • the term“heterocycle” or“heterocyclyl,” as used herein, does not include ring systems that contain one or more aromatic rings. Examples of heteroatoms include nitrogen, oxygen, or sulfur atoms, including N-oxides, sulfur oxides, and sulfur dioxides. Typically, the ring is three- to twelve- membered.
  • Such rings may be optionally fused to one or more of another heterocyclic ring(s) or cycloalkyl ring(s).
  • heterocyclic groups include, but are not limited to, tetrahydrofuran, tetrahydropyran, 1,4-dioxane, 1, 3-dioxane, piperidine, pyrrolidine, morpholine, tetrahydrothiopyran, and tetrahydrothiophene, where attachment can occur at any point on said rings, as long as attachment is chemically feasible.
  • “morpholine” refers to morpholin-2-yl, morpholin-3-yl, and morpholin-4- yi.
  • the“heterocycle” or“heterocyclyl” group can attach through either a carbon atom or any heteroatom, to the extent that attachment at that point is chemically feasible.
  • “heterocyclyl” would include pyrrolidin- 1-yl, pyrrolidin-2-yl, and pyrrolidin- 3-yl.
  • “heterocycle” or“heterocyclyl” groups contain a nitrogen atom in the ring, attachment through the nitrogen atom can alternatively be indicated by using an“-ino” suffix with the ring name.
  • pyrrolidino refers to pyrrolidin- 1-yl.
  • halogen refers to fluorine, chlorine, bromine, or iodine.
  • an oxo substituent occurs on an otherwise saturated group, such as with an oxo- substituted cycloalkyl group (e.g., 3-oxo-cyclobutyl)
  • the substituted group is still intended to be a saturated group.
  • heteroaryl refers to a five- to fourteen-membered optionally substituted mono- or polycyclic ring system, which contains at least one aromatic ring and also contains one or more heteroatoms. Such“heteroaryl” groups may be optionally substituted as herein further described, with multiple degrees of substitution being allowed. In a polycyclic“heteroaryl” group that contains at least one aromatic ring and at least one non-aromatic ring, the aromatic ring(s) need not contain a heteroatom.
  • a polycyclic“heteroaryl” group that contains at least one aromatic ring and at least one non-aromatic ring, the aromatic ring(s) need not contain a heteroatom.
  • heteroaryl would include indolinyl. Further, the point of attachment may be to any ring within the ring system without regard to whether the ring containing the attachment point is aromatic or contains a heteroatom. Thus, for example,“heteroaryl,” as used herein, would include indolin- l-yl, indolin-3-yl, and indolin-5-yl. Examples of heteroatoms include nitrogen, oxygen, or sulfur atoms, including N-oxides, sulfur oxides, and sulfur dioxides, where feasible.
  • heteroaryl groups include, but are not limited to, furyl, thiophenyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl, isothiazolyl, 1,2,4-triazolyl, pyrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, indolyl, isoindolyl, benzo[b]thiophenyl, benzimidazolyl, benzothiazolyl, pteridinyl, and phenazinyl, where attachment can occur at any point on said rings, as long as attachment is chemically feasible.
  • “thiazolyl” refers to thiazol-2-yl, thiazol-4-yl, and thiaz-5-yl.
  • heteroaryl As used herein, when“heteroaryl” is recited as a possible substituent, the “heteroaryl” group can attach through either a carbon atom or any heteroatom, to the extent that attachment at that point is chemically feasible.
  • heterocyclylene refers to an optionally substituted bivalent heterocyclyl group (as defined above).
  • the points of attachment may be to the same ring atom or to different ring atoms, as long as attachment is chemically feasible.
  • the two points of attachment can each independently be to either a carbon atom or a heteroatom, as long as attachment is chemically feasible. Examples
  • m include, but are not limited to, , , where the asterisks indicate points of attachment.
  • heteroarylene refers to an optionally substituted bivalent heteroaryl group (as defined above).
  • the points of attachment may be to the same ring atom or to different ring atoms, as long as attachment is chemically feasible.
  • the two points of attachment can each independently be to either a carbon atom or a heteroatom, as long as attachment is chemically feasible.
  • Examples include, but are not limited to,
  • methylaminocarbonylmethyl refers to -CH 2 -C(0)-NH-CH 3 .
  • substituted refers to substitution of one or more hydrogens of the designated moiety with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated, provided that the substitution results in a stable or chemically feasible compound.
  • a stable compound or chemically feasible compound is one in which the chemical structure is not substantially altered when kept at a temperature from about -80° C to about +40° C, in the absence of moisture or other chemically reactive conditions, for at least a week, or a compound which maintains its integrity long enough to be useful for therapeutic or prophylactic administration to a subject.
  • phrases“substituted with one or more...” or“substituted one or more times...” refer to a number of substituents that equals from one to the maximum number of substituents possible based on the number of available bonding sites, provided that the above conditions of stability and chemical feasibility are met.
  • the various functional groups represented will be understood to have a point of attachment at the functional group having the hyphen or dash (-) or an asterisk (*).
  • -CH2CH2CH3 it will be understood that the point of attachment is the CH2 group at the far left. If a group is recited without an asterisk or a dash, then the attachment point is indicated by the plain and ordinary meaning of the recited group.
  • R d R d ), or multiple constituents, its definition on each occurrence is independent of its definition on every other occurrence.
  • multi-atom bivalent species are to be read from left to right. For example, if the specification or claims recite A-D-E and D is defined as -OC(O)-, the resulting group with D replaced is: A-OC(0)-E and not A-C(0)0-E.
  • the term“optionally” means that the subsequently described event(s) may or may not occur.
  • administer means to introduce, such as to introduce to a subject a compound or composition.
  • the term is not limited to any specific mode of delivery, and can include, for example, intravenous delivery, transdermal delivery, oral delivery, nasal delivery, and rectal delivery.
  • the administering can be carried out by various individuals, including, for example, a health-care professional (e.g., physician, nurse, etc.), a pharmacist, or the subject (i.e., self- administration).
  • a health-care professional e.g., physician, nurse, etc.
  • a pharmacist e.g., a pharmacist
  • the subject i.e., self- administration
  • “treat” or“treating” or“treatment” can refer to one or more of delaying the progress of a disease or condition, controlling a disease or condition, delaying the onset of a disease or condition, ameliorating one or more symptoms characteristic of a disease or condition, or delaying the recurrence of a disease or condition or characteristic symptoms thereof, depending on the nature of a disease or condition and its characteristic symptoms.
  • “Treat” or “treating” or “treatment” may also refers to inhibiting the disease, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both, and to inhibiting at least one physical parameter that may or may not be discernible to the subject.
  • treatment refers to delaying the onset of the disease or at least one or more symptoms thereof in a subject which may be exposed to or predisposed to a disease even though that subject does not yet experience or display symptoms of the disease.
  • subject may refer any mammal such as, but not limited to, humans.
  • the subject is a human.
  • the host is a human who exhibits one or more symptoms characteristic of a disease or condition.
  • the term“subject” does not require one to have any particular status with respect to any hospital, clinic, or research facility (e.g., as an admitted patient, a study participant, or the like).
  • the subject may be "a subject in need thereof.”
  • “Therapeutically effective amount” refers to the amount of a compound that, when administered to a subject for treating a disease, or at least one of the clinical symptoms of a disease, is sufficient to affect such treatment of the disease or symptom thereof.
  • the “therapeutically effective amount” may vary depending, for example, on the compound, the disease and/or symptoms of the disease, severity of the disease and/or symptoms of the disease or disorder, the age, weight, and/or health of the subject to be treated, and the judgment of the prescribing physician. An appropriate amount in any given instance may be ascertained by those skilled in the art or capable of determination by routine experimentation.
  • the term“compound of the invention” includes free acids, free bases, and any salts thereof of the compound of Formula (I).
  • phrases such as “compound of embodiment 1” or“compound of claim 1 refer to any free acids, free bases, and any salts thereof that are encompassed by embodiment 1 or claim 1, respectively.
  • the present invention provides methods of increasing expression of HbF in cells by contacting certain cells, for example erythroid or retinal pigment epithelial (RPE) cells, with a therapeutically effective amount of a compound of the invention.
  • the present invention provides methods of increasing expression of HbF in cells by administering a compound of the invention to a subject in need thereof.
  • the expression of HbF is increased such that HbF is greater than or equal to 1%, 2%, 3%, 4%, 5%, 6%, 7%,
  • the expression of HbF is increased such that HbF is increased by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, percentage point of the total hemoglobin in a subject or in a sample taken from a subject relative to a baseline sample taken prior to treatment of the subject.
  • the expression of HbF is increased such that HbF is greater than or equal to 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 80%, or 90% of the total hemoglobin in a subject or in a sample taken from a subject.
  • the methods can be used to compensate for a mutation in the human beta-globin gene in cells that have one or more mutations in the beta-globin gene or an expression control sequence thereof, for example mutations that result in the expression of the HbS form of hemoglobin.
  • Compensating for the mutation includes, but is not limited to, increasing the amount of HbF and reducing the amount of HbS in the subject compared to untreated subjects or prior to treatment of a subject.
  • the method of treatment results in an increase in the ratio of HbF to HbS expressed in cells in a subject in need thereof.
  • the methods can be used for treating sickle cell disease, for example sickle cell anemia, and other
  • hemoglobinopathies or thalassemias as well as complications related to SCO, for example retinopathy.
  • the present invention provides a method of inhibiting polymerization of HbS, of increasing dissolved oxygen levels in a subject’s blood, of reducing levels of reactive oxygen species (ROS), or any combination thereof by administering a compound of the invention to a subject in need thereof.
  • ROS reactive oxygen species
  • the present invention provides a method of reducing sickling in response to reduced air pressure, reduced barometric pressure, reduced partial pressure of oxygen or hypoxia, reducing incidences or rate of painful crises, reducing incidences or rate of painful crises requiring hospitalization, reducing the incidences of chest syndrome, reducing the number of transfusion events, reducing the number of units of blood transfused per event or any combination thereof by administering a compound of the invention to a subject in need thereof.
  • the reduction of incidences or rate may be over a week, month, or year.
  • the invention provides a method of treatment comprising administering a compound (or salt) of any one of embodiments 1 to 250 to a subject. In another embodiment, the invention provides a method of treatment comprising administering between 0.1 milligrams and 2 grams of a compound (or salt) of any one of embodiments 1 to 250 to a subject.
  • a compound (or salt) of any of embodiments 1 to 250 may be administered to a subject as part of a
  • the method may further include the step of determining whether the subject has one or more genetic alterations associated with SCD or first determining whether the subject has biochemical or morphological alterations associated with SCD.
  • the method may further include the step of determining whether administration of a compound of the invention has increased expression of HbF, decreased biomarkers associated with SCD such ROS, or reduced the symptoms associated with SCD.
  • the method may further comprise the step of administering a higher dose of a compound of the invention if the subject has not increased expression of HbF, does not have decreased biomarkers associated with SCD such ROS, or does not have reduced the symptoms associated with SCD.
  • Methods for treating SCD or complications thereof described herein may also include administering a compound of the invention in combination with or alternation with HU or an Nrf2 activator.
  • the combination may be administered in amounts effective to induce or increase expression of HbF.
  • the compounds of the invention and the combinations described herein can be used to treat subjects with one or more mutations in the beta-globin gene (HBB gene). Mutations in the beta globin gene can cause sickle cell disease, beta thalassemia, or related diseases or conditions thereof. As discussed in more detail below, mutations in the beta-globin gene can be identified before or after
  • compositions can be any suitable pharmaceutically acceptable pharmaceutically acceptable pharmaceutically acceptable carrier.
  • the compositions can be any suitable pharmaceutically acceptable carrier.
  • compositions are administered to a subject with one or more mutations in the beta-globin gene before or after the onset of clinical symptoms. Therefore, in some embodiments, the compositions are administered to a subject that has been diagnosed with one or more mutations in the beta-globin gene, but does not yet exhibit clinical symptoms. In some embodiments, the compositions are administered to a subject that is exhibiting one or more symptoms of a disease, condition, or syndrome associated with, or caused by one or more mutations in the beta-globin gene.
  • Sickle cell disease typically arises from a mutation substituting thymine for adenine in the sixth codon of the beta-chain gene of hemoglobin (i.e., GAG to GTG of the HBB gene). This mutation causes glutamate to valine
  • HbS has the physical properties of forming polymers under deoxy conditions.
  • SCD is typically an autosomal recessive disorder. Therefore, in some embodiments, the disclosed compositions and methods are used to treated a subject homozygous for an autosomal recessive mutation in beta-chain gene of hemoglobin (i.e., homozygous for sickle cell hemoglobin (HbS)). Also referred to as HbSS disease or sickle cell anemia (the most common form), subjects homozygote for the S globin typically exhibit a severe or moderately severe phenotype and have the shortest survival of the hemoglobinop athies .
  • Sickle cell trait or the carrier state is the heterozygous form characterized by the presence of around 40% HbS, absence of anemia, inability to concentrate urine (isosthenuria), and hematuria. Under conditions leading to hypoxia, it may become a pathologic risk factor. Accordingly, in some embodiments, the disclosed compositions and methods are used to treat a subject heterozygous for an autosomal recessive mutation in the beta- chain gene of hemoglobin (i.e., heterozygous for HbS).
  • Beta-thalassemias are a group of inherited blood disorders caused by a variety of mutational mechanisms that result in a reduction or absence of synthesis of b-globin and leading to accumulation of aggregates of unpaired, insoluble a-chains that cause ineffective erythropoiesis, accelerated red cell destruction, and severe anemia.
  • Subjects with beta-thalassemia exhibit variable phenotypes ranging from severe anemia to clinically asymptomatic individuals.
  • the genetic mutations present in b-thalassemias are diverse, and can be caused by a number of different mutations.
  • thalassemia minor thalassemia intermedia
  • thalassemia major thalassemia major.
  • HbSC disease A subject that is a double heterozygote for HbS and HbC (HbSC disease) is typically characterized by symptoms of moderate clinical severity.
  • HbE hemoglobin E
  • a subject that is a double heterozygote for HbS and HbE has HbS/HbE syndrome, which usually causes a phenotype similar to HbS/b+ thalassemia, discussed below.
  • beta-thalassemia mutations Some mutations in the beta-globin gene can cause other structural variations of hemoglobin or can cause a deficiency in the amount of b-globin being produced. These types of mutations are referred to as beta-thalassemia mutations.
  • the absence of beta-globin is referred to as beta-zero (6-0) thalassemia.
  • a subject that is a double heterozygote for HbS and 6-0 thalassemia i.e., HbS/6-0 thalassemia
  • a reduced amount of beta-globin is referred to as 6-plus (6+) thalassemia.
  • a subject that is a double heterozygote for HbS and 6+ thalassemia i.e., HbS/6+ thalassemia
  • HbS/6+ thalassemia can have mild-to-moderate severity of clinical symptoms with variability among different ethnicities.
  • Rare combinations of HbS with other abnormal hemoglobins include HbD Los Angeles, G- Philadelphia, HbO Arab, and others.
  • compositions and methods are used to treat a subject with an HbS/6-0 genotype, an HbS/6+ genotype, an HBSC genotype, an HbS/HbE genotype, an HbD Los Angeles genotype, a G-Philadelphia genotype, or an abHbO Arab genotype.
  • retinopathy due to SCD can also be treated by
  • administering an effective amount of a compound of the invention, optionally in combination or alternation with HU or with an Nrf2 activator in amounts effective to induce expression of HbF in retinal cells, for example in RPE cells.
  • Administration of a compound of the invention optionally in combination with HU or with an Nrf2 activator may reduce or inhibit the formation of occlusions in the peripheral retina of a sickle cell patient.
  • red blood cells are the primary producers of hemoglobin
  • reports indicate that other, non-hematopoietic cells including, but not limited to, macrophage, retinal pigment cells, and alveolar epithelial cells such as alveolar type II (ATII) cells and Clara cells also synthesize hemoglobin.
  • ATII alveolar type II
  • compositions disclosed herein are used to increase HbF
  • compositions disclosed herein are used to increase HbF expression in non-erythroid cells at interfaces where oxygen- carbon dioxide diffusion occurs, including, but not limited to the eyes and lungs.
  • compositions are used to induce, increase, or enhance hemoglobin synthesis in retinal pigment cells in an effective amount to prevent, reduce, or alleviate one or more symptoms of age-related macular degeneration or diabetic retinopathy.
  • compositions disclosed herein are administered to a subject in an amount effective to treat one or more symptoms of sickle cell disease, a beta-thalassemia, or a related disorder.
  • Beta-thalassemia can include symptoms such as anemia, fatigue and weakness, pale skin or jaundice, protruding abdomen with enlarged spleen and liver, dark urine, abnormal facial bones, poor growth, and poor appetite.
  • physiological changes in RBCs can result in a disease with the following signs: (1) hemolytic anemia; (2) vaso- occlusive crisis; and (3) multiple organ damage from microinfarcts, including heart, skeleton, spleen, and central nervous system.
  • compositions for Use in Treating SCD and Related Disorders III. Compositions for Use in Treating SCD and Related Disorders
  • a compound of Formula (I) has the structure shown below
  • G is hydrogen, -Ci- 8 alkyl, -C3- 10 cycloalkyl, -Ci- 6 alkylene -C3- 10 cycloaklyl, heterocyclyl, -Ci- 6 alkylene- C3- 10 heterocyclyl, phenyl, heteroaryl, or NR h R k , where the alkyl, alkylene, cycloalkyl, heterocyclyl, phenyl, and heteroaryl groups are optionally substituted one or more times with substituents independently selected from R c ; or G is -CH 2 Y 3 , -CH 2 CH 2 Y 3 , -CH 2 CH 2 CH 2 Y 3 , - CH(CH 3 )CH 2 Y 3 , -
  • tetrahydropyran-4-yl tetrahydrofuran-2-yl, morpholin-2-yl, morpholin-4-yl, piperidin- 1-yl, 4-hydroxy-piperidin- l-yl, 3-hydroxy-piperidin- l-yl, -NH- C(0)-CH3, -NH-C(0)-CH 2 CH 3 , tetrahydrofuran-2-yl-methyloxy, or -C(0)-Y 4 , where Y 4 is -OH, -OCH3, -OCH 2 CH 3 , -OC(CH 3 ) 3 , -NH 2 , -NH-CH3, -NH- CH 2 CH3, -N(CH 3 ) 2 , -N(CH 2 CH 3 ) 2 , morpholin-4-yl, 4-methyl-piperazin- l-yl, pyrrolidin- l-yl, or piperazin- l-yl;
  • L is -CH 2 -C(0)N(R 6 )-, -C(0)N(R 6 )-, -C(0)-0-, -S0 2 -, -C(0)-, heteroarylene optionally substituted one or more times with substituents independently selected from R x , or heterocyclylene optionally substituted one or more times with
  • R 1 is hydrogen, R a , phenyl, or heteroaryl, where the phenyl and heteroaryl groups are optionally substituted one or more times with substituents independently selected from R x ;
  • R 2 is R b ;
  • R 3 is hydrogen, -Ci- 6 alkyl, or -Ci- 6 alkylene-Ca-io cycloaklyl, where the alkyl,
  • alkylene, and cycloalkyl groups are optionally substituted one or more times with substituents independently selected from R z ;
  • R 4 is -Ci-6 alkyl or -Ci-6 alkylene- C3- 10 cycloaklyl, where the alkyl, alkylene, and
  • cycloalkyl groups are optionally substituted one or more times with
  • R 6 is hydrogen, -Ci-6 alkyl, -Ci-6 alkylene-Ca-io cycloaklyl, where the alkyl, alkylene, and cycloalkyl groups are optionally substituted one or more times with substituents independently selected from R x ;
  • alkyl, cycloalkyl, and heterocyclyl groups are optionally
  • R b is
  • alkyl, cycloalkyl, heterocyclyl, phenyl, and heteroaryl groups are optionally substituted one or more times with substituents independently selected from R z ; a) -halogen,
  • alkylene, alkyl, cycloalkyl, heterocyclyl, phenyl, and heteroaryl groups are optionally substituted one or more times with substituents independently selected from R x ;
  • R d and R e are independently hydrogen, Ci- 6 alkyl, or C3- 10 cycloalkyl, where the alkyl and cycloalkyl groups are optionally substituted one or more times with substituents independently selected from R ⁇ ; or, if R d and R e are both attached to the same nitrogen atom, together with that nitrogen atom may optionally form a heterocyclic ring selected from the group consisting of azetidino, pyrrolidino, pyrazolidino, imidazolidino, oxazolidino, isoxazolidino, thiazolidino, isothiazolidino, piperidino, piperazino, morpholino,
  • R f and Re are independently hydrogen, Ci- 6 alkyl, C3- 10 cycloalkyl, phenyl, or heteroaryl, where the alkyl, cycloalkyl, phenyl, and heteroaryl groups are optionally substituted one or more times with substituents independently selected from R z ; or, if R f and Re are both attached to the same nitrogen atom, together with that nitrogen atom may optionally form a heterocyclic ring selected from the group consisting of azetidino, pyrrolidino, pyrazolidino, imidazolidino, oxazolidino, isoxazolidino, thiazolidino, isothiazolidino, piperidino, piperazino, morphohno, thiomorpholino, and azepano, where each ring is optionally substituted one or more times with substituents independently selected from R ;
  • R f and Re are independently hydrogen, Ci- 6 alkyl,
  • R h and R k are independently hydrogen, Ci- 6 alkyl, C3- 10 cycloalkyl, heterocyclyl, phenyl, or heteroaryl, where the alkyl, cycloalkyl, heterocyclyl, phenyl, and heteroaryl groups are optionally substituted one or more times with substituents independently selected from R x ; or, if R h and R k are both attached to the same nitrogen atom, together with that nitrogen atom may optionally form a heterocyclic ring selected from the group consisting of azetidino, pyrrolidino, pyrazolidino, imidazolidino, oxazolidino, isoxazolidino, thiazolidino, isothiazolidino, piperidino, piperazino, morphohno,
  • n n-heterocyclyl optionally substituted one or more times with substituents selected independently from the group consisting of halogen, -OH, -O- C 1 - 6 alkyl, -NH 2 , -NH-CI-6 alkyl, and -N(CI-6 alkyl) 2 ,
  • substituents selected independently from the group consisting of halogen, -OH, -O-Ci- 6 alkyl, -NH 2 , -NH-C 1-6 alkyl, and -N(C I-6 alkyl) 2 ,
  • -O-Ci- 6 alkyl optionally substituted one or more times with substituents selected independently from the group consisting of halogen, -OH, -O- C 1 - 6 alkyl, -NH 2 , -NH-CI-6 alkyl, and -N(CI-6 alkyl) 2 ,
  • substituents selected independently from the group consisting of halogen, -OH, -O-Ci- 6 alkyl, -NH 2 , -NH-C 1-6 alkyl, and -N(C I-6 alkyl) 2 , t) -C(0)-0-C 1-6 alkyl, optionally substituted one or more times with
  • substituents selected independently from the group consisting of halogen, -OH, -O-Ci- 6 alkyl, -NH2, -NH-C 1-6 alkyl, and -N(C I-6 alkyl)2, w) -C(O) -NH-C 1-6 alkyl, optionally substituted one or more times with
  • substituents selected independently from the group consisting of halogen, -OH, -O-Ci- 6 alkyl, -NH2, -NH-C 1-6 alkyl, and -N(C I-6 alkyl)2, x) -C(0)-N(Ci- 6 alkyl) 2 , optionally substituted one or more times with
  • substituents selected independently from the group consisting of halogen, -OH, -O-Ci- 6 alkyl, -NH2, -NH-C 1-6 alkyl, and -N(C I-6 alkyl)2, y) -S(0) 2 -NH-C I-6 alkyl, optionally substituted one or more times with
  • substituents selected independently from the group consisting of halogen, -OH, -O-Ci- 6 alkyl, -NH2, -NH-C 1-6 alkyl, and -N(C I-6 alkyl)2, z) -S(0) 2 -N(Ci- 6 alkyl) 2 , optionally substituted one or more times with
  • substituents selected independently from the group consisting of halogen, -OH, -O-Ci- 6 alkyl, -NH2, -NH-C 1-6 alkyl, and -N(C I-6 alkyl)2, aa)-NH-C(0)-Ci- 6 alkyl, optionally substituted one or more times with
  • substituents selected independently from the group consisting of halogen, -OH, -O-Ci- 6 alkyl, -NH2, -NH-C 1-6 alkyl, and -N(C I-6 alkyl)2, or
  • substituents selected independently from the group consisting of halogen, -OH, -O-Ci- 6 alkyl, -NH2, -NH-C 1-6 alkyl, and -N(C I-6 alkyl)2;
  • halogen selected independently from the group consisting of halogen, -OH, -O- C1-6 alkyl, -NH2, -NH-CI- 6 alkyl, and -N(CI- 6 alkyl)2, c) -heteroaryl, optionally substituted one or more times with substituents selected independently from the group consisting of halogen, -OH, -O- Ci-6 alkyl, -NH2, -NH-Ci-6 alkyl, and -N(Ci-6 alkyl) 2 ,
  • v is an integer from 0 to 4, and
  • w is an integer from 0 to 2.
  • Embodiment 2 A compound according to embodiment 1 wherein
  • G is hydrogen, -Ci-s alkyl, -C 3 - 10 cycloalkyl, -Ci-6 alkylene-Gv io cycloaklyl,
  • heterocyclyl phenyl, heteroaryl, or NR h R k , where the alkyl, alkylene, cycloalkyl, heterocyclyl, phenyl, and heteroaryl groups are optionally substituted one or more times with substituents independently selected from R c ; or G is -CH2Y 3 , -CH2CH2Y 3 , -CH2CH2CH2Y 3 , -CH(CH 3 )CH 2 Y 3 , -
  • alkylene, alkyl, cycloalkyl, heterocyclyl, phenyl, and heteroaryl groups are optionally substituted one or more times with substituents independently selected from R x ;
  • R h and R k are independently hydrogen, Ci- 6 alkyl, C3-10 cycloalkyl, phenyl, or
  • heteroaryl where the alkyl, cycloalkyl, phenyl, and heteroaryl groups are optionally substituted one or more times with substituents independently selected from R x ; or, if R h and R k are both attached to the same nitrogen atom, together with that nitrogen atom may optionally form a heterocyclic ring selected from the group consisting of azetidino, pyrrolidino, pyrazolidino, imidazolidino, oxazolidino, isoxazolidino, thiazolidino, isothiazolidino, piperidino, piperazino, morphohno, thiomorpholino, and azepano, where each ring is optionally substituted one or more times with substituents
  • Embodiment 3 A compound according to embodiment 2, wherein
  • R 3 is hydrogen
  • Embodiment 4 A compound according to embodiment 2, wherein
  • R 3 is methyl
  • Embodiment 7 A compound according to any one of embodiments 2 to 6, wherein v is an integer from 0 to 2.
  • Embodiment 8 A compound according to any one of embodiments 2 to 6, wherein v is 0 or 1.
  • Embodiment 9 A compound according to any one of embodiments 2 to 6, wherein v is 1.
  • Embodiment 10 A compound according to any one of embodiments 2 to 6, wherein v is 1, and R 2 is attached at either the 5-position or the 6-position of the
  • Embodiment 11 A compound according to any one of embodiments 2 to 6, wherein v is 1, and R 2 is attached at the 6-position of the benzothiazole ring.
  • Embodiment 12 A compound according to any one of embodiments 2 to 68, wherein v is 2, and one R 2 is attached at the 6-position of the benzothiazole ring.
  • Embodiment 13 A compound according to any one of embodiments 2 to 6, wherein v is 2, and R 2 is attached at the 5-position and the 6-position of the
  • Embodiment 14 A compound according to any one of embodiments 2 to 13, wherein R 2 is -halogen, -Ci- 6 alkyl, -CF3, -OCF3, -0-R f , or -S(0) w -R f , where the alkyl group is optionally substituted one or more times with substituents independently selected from R z .
  • Embodiment 15 A compound according to any one of embodiments 2 to 13, wherein R 2 is -halogen, -methyl, -CF3, -OCF3, -SCF3, -O-heteroaryl, or -S(0) 2 -CH 3 .
  • Embodiment 16 A compound according to any one of embodiments 2 to 13, wherein R 2 is selected from -Cl, -F, -CF3, and -OCF3.
  • Embodiment 17 A compound according to any one of embodiments 2 to 13, wherein R 2 is -OCF3.
  • Embodiment 18 A compound according to any one of embodiments 2 to 13, wherein R 2 is -CF 3 .
  • Embodiment 19 A compound according to any one of embodiments 2 to 13, wherein R 2 is -F.
  • Embodiment 20 A compound according to any one of embodiments 2 to 13, wherein R 2 is -Cl.
  • Embodiment 21 A compound according to any one of embodiments 2 to 20, wherein R 4 is -methyl, -ethyl, -n-propyl, -isopropyl, -n-butyl, -sec-butyl, -isobutyl, -tert- butyl, -(CH 2 ) I -2-OCH 3 , -(CH 2 ) I. 2-F, -(CH 2 ) I.2 -C1, -(CH 2 ) I.2 -OCF 3 , -(CH 2 ) I.
  • Embodiment 22 A compound according to any one of embodiments 2 to 21, wherein R 4 is -methyl, -ethyl, -isopropyl, -isobutyl, -CH 2 CH 2 -OCH 3 , -CH 2 CH 2 -F, or -CH 2 CH 2 -NH 2 .
  • Embodiment 23 A compound according to any one of embodiments 2 to 22, wherein R 4 is -methyl, -ethyl, -isopropyl, or -isobutyl.
  • Embodiment 24 A compound according to any one of embodiments 2 to 23, wherein R 4 is -methyl.
  • Embodiment 25 A compound according to any one of embodiments 2 to 23, wherein R 4 is -ethyl.
  • Embodiment 26 A compound according to any one of embodiments 2 to 21, wherein R 4 is -(CH 2 )2-OCH 3 , -(CH 2 ) 2 -F, -(CH 2 )2-C1, -(CH 2 )2-OCF 3 , -(CH 2 )2-NH2, -(CH 2 ) 2 - CN, -(CH 2 ) 2 -0H, -(CH 2 ) 2 -CF 3 , -(CH 2 ) 2 -C0 2 H, -(CH 2 ) 2 -SH, -(CH 2 ) 2 -SCH 3 , or -(CH2)2-S(0) 2 CH 3 .
  • Embodiment 27 A compound according to any one of embodiments 2 to 26, wherein R 1 is selected from hydrogen, -OCH 3 , -F, -Cl, -NH2, -cyano, -OH, -
  • CF 3 -OCF 3 , -SH, -S-Ci-6 alkyl, -S(0) 2 -Ci- 6 alkyl, -CO2H, -NH-Ci-e alkyl, -N(Ci-6 alkyl)2, and -NH-CI-6 alkyl.
  • Embodiment 28 A compound according to any one of embodiments 2 to 26, wherein R 1 is selected from -OCH 3 , -F, -CF 3 ⁇ 4 -OCF 3 ⁇ 4 -N(CH 3 ) 2 , -N(CH 2 CH 3 ) 2 , and -
  • Embodiment 29 A compound according to any one of embodiments 2 to 26, wherein R 1 is selected from hydrogen, -OCH3, and -F.
  • Embodiment 30 A compound according to any one of embodiments 2 to 26, wherein R 1 is hydrogen.
  • Embodiment 31 A compound according to any one of embodiments 2 to 30, wherein
  • G is hydrogen, -Ci- 8 alkyl, -C3- 10 cycloalkyl, -Ci- 6 alkylene-Ca-s cycloaklyl,
  • heterocyclyl or NR h R k , where the alkyl, alkylene, cycloalkyl, and
  • heterocyclyl groups are optionally substituted one or more times with substituents independently selected from R c ; or G is -CH2Y 3 , -CH2CH2Y 3 , - CH2CH2CH2Y 3 , -CH(CH 3 )CH 2 Y 3 , -CH 2 CH(Y 3 )CH 3 , -CHECKS, -
  • L is -CH 2 -C(0)N(R 6 )-, -C(0)N(R 6 )-, -C(0)-0-, -SO2-, -C(O)-, or heterocyclylene optionally substituted one or more times with substituents independently selected from R x ; or the group -L-G is -cyano;
  • R 1 is hydrogen or R a ;
  • R h and R k are independently hydrogen, Ci- 6 alkyl, or C3- 10 cycloalkyl, where the
  • alkyl, and cycloalkyl groups are optionally substituted one or more times with substituents independently selected from R x ; or, if R h and R k are both attached to the same nitrogen atom, together with that nitrogen atom may optionally form a heterocyclic ring selected from the group consisting of azetidino, pyrrolidino, pyrazolidino, imidazolidino, oxazolidino, isoxazolidino, thiazolidino, isothiazolidino, piperidino, piperazino, morpholino,
  • R x is R .
  • Embodiment 32 A compound according to any one of embodiments 2 to 31, wherein -L-G is not -cyano.
  • Embodiment 33 A compound according to any one of embodiments 2 to 32, wherein -L-G is -C(0)NR h R k .
  • Embodiment 34 A compound according to any one of embodiments 2 to 32, wherein L is -C(0)N(R 6 )- or -C(0)-0-.
  • Embodiment 35 A compound according to any one of embodiments 2 to 32, wherein L is -C(0)N(R 6 )-.
  • Embodiment 36 A compound according to any one of embodiments 2 to 32, wherein L is not -CH 2 -C(0)N(R 6 )-.
  • Embodiment 37 A compound according to any one of embodiments 2 to 32, wherein L is -C(0)-0-.
  • Embodiment 38 A compound according to any one of embodiments 2 to 32, wherein L is -C(O)-.
  • Embodiment 39 A compound according to any one of embodiments 2 to 32, wherein L is -S(0) 2 -.
  • Embodiment 40 A compound according to any one of embodiments 2 to 30, wherein L is heteroarylene optionally substituted one or more times with substituents independently selected from R x .
  • Embodiment 41 A compound according to any one of embodiments 2 to 40, wherein R 6 is hydrogen.
  • Embodiment 42 A compound according to any one of embodiments 2 to 40, wherein R 6 is hydrogen or -methyl.
  • Embodiment 43 A compound according to any one of embodiments 2 to 42, wherein G is hydrogen, -Ci- 8 alkyl, -C3-10 cycloalkyl, or -Ci- 6 alkylene-Ca- 8 cycloaklyl, where the alkyl, cycloalkyl, and alkylene groups are optionally substituted one or more times with substituents independently selected from R x .
  • Embodiment 44 A compound according to any one of embodiments 2 to 42, wherein G is -H, -methyl, -ethyl, -n-propyl, -isopropyl, -isobutyl, -CH2Y 3 , -
  • Embodiment 45 A compound according to any one of embodiments 2 to 42, wherein G is -methyl, -ethyl, -n-propyl, -isopropyl, or -isobutyl, where each is
  • substituents independently selected from -CF 3 , -OCF 3 , -OCH 3 , -OCH2CH 3 , -F, -OH, -0(CH 2 ) 2 -0H, -0(CH 2 ) 2 -F, -SCH 3 , -SCH 2 CH 3 , -NH-CH 3 , -NH-CH 2 CH 3 , and -N(CH 3 ) 2 .
  • Embodiment 46 A compound according to any one of embodiments 2 to 42, wherein G is H.
  • Embodiment 47 A compound according to any one of embodiments 2 to 42, wherein G is C 1-8 alkyl optionally substituted one or more times with halogen.
  • Embodiment 48 A compound according to any one of embodiments 2 to 42, wherein G is C 3. l o cycloalkyl optionally substituted one or more times with halogen.
  • Embodiment 49 A compound according to any one of embodiments 2 to 42, wherein G is heterocyclyl optionally substituted one or more times with halogen.
  • Embodiment 50 A compound according to any one of embodiments 2 to 42, wherein G is -Ci-e alkylene-Ca- io cycloalkyl optionally substituted one or more times with halogen.
  • Embodiment 51 A compound according to any one of embodiments 2 to 42, wherein G is NR h R k .
  • Embodiment 52 A compound according to any one of embodiments 2 to 42, wherein G is -CH 2 -R c .
  • Embodiment 53 A compound according to any one of embodiments 2 to 42, wherein G is -CH 2 CH 2 -R c .
  • Embodiment 54 A compound according to any one of embodiments 2 to 42, wherein G is -CH 2 CH 2 CH 2 -R C .
  • Embodiment 55 A compound according to any one of embodiments 2 to 42, wherein G is -CH(CH 3 )CH 2 R C .
  • Embodiment 56 A compound according to any one of embodiments 2 to 42, wherein
  • G is -CH 2 CH(R°)CH 3 .
  • Embodiment 57 A compound according to any one of embodiments 2 to 42, wherein G is -CH(R C )CH 3 .
  • Embodiment 58 A compound according to any one of embodiments 2 to 42, wherein G is -CH 2 C(R c )(CH 3 ) 2 .
  • Embodiment 59 A compound according to any one of embodiments 2 to 42, wherein G is -C(R c )(CH 3 ) 2 .
  • Embodiment 60 A compound according to any one of embodiments 2 to 42, wherein G is imidazol-2-yl, thiazol-2yl, oxazol-2-yl, pyrazoll-yl, furan-2yl, thiophen-2- yl, pyrrol- 1-yl, lH-l,2,4-triazolyl-3-yl, 5-methyl- 1H- 1,2, 4- triazolyl-3-yl, -(CH 2 )i- 3 -(imidazol-2-yl), -(CH 2 )i- 3 -(thiazol-2yl), -(CH 2 )i- 3 -(oxazol-2-yl), - (CH 2 )i-3-(pyrazoll-yl), -(CH 2 )i- 3 -(furan-2yl), -(CH 2 )i- 3 -(thiophen-2-yl), - (CH2)i-3-(pyrrol- l-
  • Embodiment 61 A compound according to any one of embodiments 2 to 60, wherein the compound is in its free (non-salted) form.
  • Embodiment 62 A compound according to any one of embodiments 2 to 60, wherein the compound is in the form of a pharmaceutically acceptable salt.
  • Embodiment 63 A compound according to any one of embodiments 1 to 62, wherein any“heterocyclyl” group present in the compound is selected from the group consisting of: azetidin-l-yl, azetidin-2-yl, azetidin-3-yl, pyrrolidin- 1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothiophen-2-yl, tetrahydrothiophen-3-yl, pyrazolidin- 1-yl, pyrazolidin-3-yl, pyrazolidin-4-yl, imidazolidin-l-yl, imidazolidin-2-yl, imidazolidin-4-yl, oxazolidin-2-yl, oxazolidin-3-yl, oxazolidin-4-
  • Embodiment 64 A compound according to any one of embodiments 1 to 63, wherein any“heteroaryl” group present in the compound is selected from the group consisting of: lH-pyrrol- l-yl, lH-pyrrol-2-yl, lH-pyrrol-3-yl, furan-2-yl, furan-
  • halogen independently selected from halogen, -NH2, cyano, carboxy, Ci-4 alkyl, C3-10 cycloalkyl, hydroxyl, thiol, -CF3, -OCF3, -O-C1-4 alkyl, -NH-C 1-4 alkyl, -N(Ci- 4 alkyl) 2, -S-C1.4 alkyl, -S(0) 2 -Ci. 4 alkyl, -C(0)-Ci- 4 alkyl, -C(0)0-Ci. 4 alkyl, - C(0)NH 2 , -C(0)NH-CI- 4 alkyl, -C(0)N(Ci- 4 alkyl) 2 , and phenyl.
  • Embodiment 65 A compound according to any one of embodiments 1 to 64, wherein any“heteroarylene” group present in the compound is selected from the group consisting of: lH-pyrrol-2,5-diyl, furan-2,5-diyl, thiophen-2,5-diyl, 1H- imidazol-2,4-diyl, lH-imidazol-2,5-diyl, oxazol-2,4-diyl, oxazol-2,5-diyl, thiazol-2,4-diyl, thiazol-2,5-diyl, lH- l,2,4-triazol-3,5-diyl, and 2H-isoindol- 1,3-diyl, where each of these named rings may optionally be substituted one or more times with substituents independently selected from halogen, -NH2, cyano, carboxy, -C1-4 alkyl
  • Embodiment 66 A compound according to embodiment 1.
  • Embodiment 67 A compound according to embodiment 66, wherein
  • R 3 is hydrogen
  • Embodiment 68 A compound according to embodiment 66, wherein
  • R 3 is methyl
  • Embodiment 69 A compound according to embodiment 66, wherein
  • R 3 is ethyl
  • Embodiment 70 A compound according to embodiment 66, wherein
  • R 3 is isopropyl
  • Embodiment 72 A compound according to any one of embodiments 66 to 70,
  • Embodiment 73 A compound according to any one of embodiments 66 to 72,
  • v 0, 1 or 2.
  • Embodiment 74 A compound according to any one of embodiments 66 to 72,
  • v 1 or 2.
  • Embodiment 75 A compound according to any one of embodiments 66 to 72,
  • Embodiment 76 A compound according to any one of embodiments 66 to 72,
  • Embodiment 77 A compound according to any one of embodiments 66 to 72,
  • Embodiment 78 A compound according to any one of embodiments 66 to 72, wherein v is 2, and one R 2 is attached at the 6-position of the benzothiazole ring.
  • Embodiment 79 A compound according to any one of embodiments 66 to 72,
  • Embodiment 80 A compound according to any one of embodiments 66 to 79,
  • R 2 is -halogen, -Ci- 6 alkyl, -CF3, -OCF3, -0-R f , or -S(0) w -R f , where the alkyl group is optionally substituted one or more times with substituents independently selected from R z .
  • Embodiment 81 A compound according to any one of embodiments 66 to 79,
  • R 2 is -halogen, -methyl, ethyl, isopropyl, -OCH3, -OCH2CH3, - 0CH(CH 3 ) 2 , -CFS, -OCF3, -SCFs, -S(0) 2 -CH 3 , -O-phenyl, -0-(2-pyridyl), -0-(3- pyridyl), or -0-(4-pyridyl).
  • Embodiment 82 A compound according to any one of embodiments 66 to 79,
  • R 2 is -halogen, -methyl, ethyl, isopropyl, -OCH3, -OCH2CH3, - OCH(CH 3 ) 2 , -CFS, -OCF3, -SCF 3 , -S(0) 2 -CH 3 , or -0-(3-pyridyl).
  • Embodiment 83 A compound according to any one of embodiments 66 to 79,
  • R 2 is -Cl, -F, -CFs, or -OCF3.
  • Embodiment 84 A compound according to any one of embodiments 66 to 79,
  • R 2 is -OCF3.
  • Embodiment 85 A compound according to any one of embodiments 66 to 79,
  • R 2 is -CFs.
  • Embodiment 86 A compound according to any one of embodiments 66 to 79,
  • R 2 is -F.
  • Embodiment 87 A compound according to any one of embodiments 66 to 79,
  • R 2 is -Cl
  • Embodiment 88 A compound according to any one of embodiments 66 to 79,
  • Embodiment 89 A compound according to any one of embodiments 66 to 79, wherein R 2 is methyl, ethyl, or isopropyl.
  • Embodiment 90 A compound according to any one of embodiments 66 to 79,
  • R 2 is methyl
  • Embodiment 91 A compound according to any one of embodiments 66 to 79,
  • R 2 is -OCH2CH3.
  • Embodiment 92 A compound according to any one of embodiments 66 to 79,
  • R 2 is -O-phenyl
  • Embodiment 93 A compound according to any one of embodiments 66 to 79,
  • R 2 is -0-(2-pyridyl), -0-(3-pyridyl), or -0-(4-pyridyl).
  • Embodiment 94 A compound according to any one of embodiments 66 to 79,
  • R 2 is -0-(3-pyridyl).
  • Embodiment 95 A compound according to any one of embodiments 66 to 94,
  • R 4 is -methyl, -ethyl, -n-propyl, -isopropyl, -n-butyl, -sec-butyl, -isobutyl, -tert- butyl, -(CH 2 )I-2-OCH 3 , -(CH 2 ) I-2-F, -(CH 2 )I-2-C1, -(CH2)I-2-OCF 3 , -(CH 2 ) I-2-NH2, -(CH 2 ) I-2 -CN, -(CH 2 ) I-2 -OH, -(CH 2 ) I-2 -CF 3 , -(CH 2 ) I-2 -C0 2 H, -(CH 2 ) I-2 -SH, - (CH 2 ) I-2 -SCH 3 , -(CH 2 ) I-2 -S(0) 2 CH 3 , -(CH 2 ) I-2 -OCH 2 CH 3 , -(CH 2
  • Embodiment 96 A compound according to any one of embodiments66 to 94, wherein R 4 is -methyl, -ethyl, -isopropyl, -isobutyl, -CEhCEh-OCEE, -CH2CH2-F, - CH2CH2-NH2, or -CH 2 CH2-NH-CH 3 .
  • Embodiment 97 A compound according to any one of embodiments66 to 94, wherein R 4 is -methyl, -ethyl, -isopropyl, or -isobutyl.
  • Embodiment 98 A compound according to any one of embodiments 66 to 94,
  • R 4 is methyl
  • Embodiment 99 A compound according to any one of embodiments 66 to 94,
  • R 4 is -ethyl
  • Embodiment 100 A compound according to any one of embodiments 66 to 94,
  • Embodiment 101 A compound according to any one of embodiments 66 to 94, wherein R 4 is -isobutyl.
  • Embodiment 102 A compound according to any one of embodiments 66 to 94,
  • R 4 is -CH2CH2-OCH3.
  • Embodiment 103 A compound according to any one of embodiments 66 to 94,
  • R 4 is -CH2CH2-F.
  • Embodiment 104 A compound according to any one of embodiments 66 to 94,
  • R 4 is -CH2CH2-NH2.
  • Embodiment 105 A compound according to any one of embodiments 66 to 94,
  • R 4 is -CH2CH2-NH-CH3.
  • Embodiment 106 A compound according to any one of embodiments 66 to 105, wherein
  • R 1 is hydrogen, -OCH3, -F, -Cl, -NH2, -cyano, -OH, -CF3, -OCF3, -SH, -S-Ci-6 alkyl, -S(0)2-Ci-6 alkyl, -CO2H, -NH-CI-6 alkyl, -N(Ci-6 alkyl)2, or -NH- C1-6 alkyl.
  • Embodiment 107 A compound according to any one of embodiments 66 to 105, wherein
  • R 1 is -OCH3, -F, -CF 3 , -OCF3, -N(CH 3 ) 2 , -N(CH 2 CH 3 )2, or -N(CH3)(CH 2 CH 3 ).
  • Embodiment 108 A compound according to any one of embodiments 66 to 105, wherein R 1 is hydrogen, -OCH3, or -F.
  • Embodiment 109 A compound according to any one of embodiments 66 to 105, wherein R 1 is hydrogen.
  • Embodiment 110 A compound according to any one of embodiments 66 to 105, wherein R 1 is -F.
  • Embodiment 111 A compound according to any one of embodiments 66 to 105, wherein R 1 is -OCH 3 .
  • Embodiment 112 A compound according to any one of embodiments 66 to 105
  • R 1 is -N(CH 2 CH 3 ) 2 .
  • Embodiment 113 A compound according to any one of embodiments 66 to 112, wherein G is hydrogen, -Ci- 8 alkyl, -C3- 10 cycloalkyl, -Ci- 6 alkylene -G M O cycloaklyl, heterocyclyl, -Ci- 6 alkylene- C 3.
  • Y 3 is cyclopropyl, - CF 3 , -OCF 3 , -OCH S , -OCH 2 CH 3 , -F, -Cl, -OH, -0(CH 2 ) 2 -0H, -0(CH 2 ) 2 -F, -SCHs, -S(0) 2 -CH 3 , -SCH 2 CH 3 , -S(0) 2 CH 2 CH 3 , -NH-CH 3 , -NH-CH 2 CH 3 , -
  • L is -CH 2 -C(0)N(R 6 )-, -C(0)N(R 6 )-, -C(0)-0-, -SO2-, -C(O)-, or heterocyclylene
  • R 1 is hydrogen or R a ;
  • alkylene, alkyl, cycloalkyl, and heterocyclyl groups are optionally
  • R h and R k independently are hydrogen, Ci- 6 alkyl, C3-10 cycloalkyl, or heterocyclyl, where the alkyl, cycloalkyl, and heterocyclyl groups are optionally
  • R h and R k are both attached to the same nitrogen atom, together with that nitrogen atom may optionally form a heterocyclic ring selected from azetidino, pyrrolidino, pyrazolidino, imidazolidino, oxazolidino, isoxazolidino, thiazolidino, isothiazolidino, piperidino, piperazino, morpholino,
  • R x is R .
  • Embodiment 114 A compound according to any one of embodiments 66 to 112,
  • Embodiment 115 A compound according to any one of embodiments 66 to 112,
  • L is -C(0)N(R 6 )-.
  • Embodiment 116 A compound according to embodiment 115 wherein R 6 is hydrogen.
  • Embodiment 117 A compound according to embodiment 115 wherein
  • R 6 is methyl
  • Embodiment 118 A compound according to embodiment 117 wherein
  • G is -N(CH 3 ) 2 .
  • Embodiment 119 A compound according to any one of embodiments 66 to 112, wherein -L-G is -C(0)NR h R k .
  • Embodiment 120 A compound according to embodiment 119, wherein
  • NR h R k is pyrrobdino, piperidino, piperazino, 4-methyl-piperazino, or
  • Embodiment 121 A compound according to embodiment 120, wherein
  • NR h R k is pyrrobdino, 4-(2-hydroxyethyl)-piperazino, or 4-(3-hydroxypropyl)- piperidino.
  • Embodiment 122 A compound according to embodiment 119, wherein
  • NRh R k is N[(CH 2 ) 2 -OH] 2 .
  • Embodiment 123 A compound according to any one of embodiments 66 to 114, wherein L is not -CH 2 -C(0)N(R 6 )-.
  • Embodiment 124 A compound according to any one of embodiments 66 to 123, wherein L is not heterocyclylene.
  • Embodiment 125 A compound according to any one of embodiments 66 to 112, wherein L is -S(0) 2 -.
  • Embodiment 126 A compound according to embodiment 125, wherein
  • G is methyl or -CF3.
  • Embodiment 127 A compound according to any one of embodiments 66 to 112, wherein
  • L is heteroarylene optionally substituted one or more times with substituents independently selected from R x .
  • Embodiment 128 A compound according to embodiment 127, wherein
  • Embodiment 129 A compound according to any one of embodiments 66 to 112, wherein L is -C(0)-0-.
  • Embodiment 130 A compound according to embodiment 129, wherein
  • G is hydrogen, or -Ci- 8 alkyl, where the alkyl group is optionally substituted one or more times with substituents independently selected from R c .
  • Embodiment 131 A compound according to embodiment 130, wherein
  • G is methyl or ethyl.
  • Embodiment 132 A compound according to embodiment 130, wherein
  • Embodiment 133 A compound according to any one of embodiments 66 to 116, wherein
  • G is -Ci- 8 alkyl, -C3- 10 cycloalkyl, -Ci- 6 alkylene-Ca-io cycloaklyl, heterocyclyl, or -Ci- 6 alkylene-Ca-io heterocyclyl, where the alkyl, alkylene, cycloalkyl, and heterocyclyl groups are optionally substituted one or more times with substituents independently selected from R c .
  • Embodiment 134 A compound according to embodiment 133, wherein
  • G is -Ci- 8 alkyl optionally substituted one or more times with substituents independently selected from R c .
  • Embodiment 135 A compound according to embodiment 134, wherein
  • G is methyl, ethyl, isopropyl, n-propyl, n-butyl, sec-butyl, or isobutyl.
  • Embodiment 136 A compound according to embodiment 134, wherein
  • G is methyl, ethyl, or n-propyl.
  • Embodiment 137 A compound according to embodiment 134, wherein
  • G is 2-fluoroethyl, 2,2-difLuoroethyl, or 2,2,2-trifluoroethyl.
  • Embodiment 138 A compound according to embodiment 134, wherein
  • G is 2-cyanoethyl.
  • Embodiment 139 A compound according to embodiment 134, wherein
  • G is -Ci- 8 alkyl substituted once by -C(0)-0-R h .
  • Embodiment 140 A compound according to embodiment 139, wherein
  • Embodiment 141 A compound according to embodiment 140, wherein R h is hydrogen or methyl.
  • Embodiment 142 A compound according to embodiment 139, wherein
  • G is -CH 2 CH 2 -C(0)-0-R h .
  • Embodiment 143 A compound according to embodiment 142, wherein
  • R h is hydrogen or methyl.
  • Embodiment 144 A compound according to embodiment 139, wherein
  • G is -C(CH 3 ) 2 -C(0)-0-R h .
  • Embodiment 145 A compound according to embodiment 144, wherein
  • R h is hydrogen or methyl.
  • Embodiment 146 A compound according to embodiment 139, wherein
  • G is -CH(CH 3 )-C(0)-0-R h .
  • Embodiment 147 A compound according to embodiment 146, wherein
  • R h is hydrogen or methyl.
  • Embodiment 148 A compound according to embodiment 134, wherein
  • G is -Ci- 8 alkyl substituted once by -C(0)NR h R k .
  • Embodiment 149 A compound according to embodiment 148, wherein
  • G is CH 2 -C(0)-NR h R k .
  • Embodiment 150 A compound according to embodiment 149, wherein
  • NR h R k is methylamino, dimethylamino, or diethylamino.
  • Embodiment 151 A compound according to embodiment 149, wherein
  • NR h R k is thiomorpholino or 1, 1-dioxothiomorpholino.
  • Embodiment 152 A compound according to embodiment 149, wherein
  • NR h R k is morpholino, pyrrolidino, piperidino, piperazino, or 4- methylpiperazino.
  • Embodiment 153 A compound according to embodiment 149, wherein
  • NR h R k is pyrrolidino, 3-hydroxy-pyrrolidino, 3-methoxy-pyrrolidino, 3-amino- pyrrolidino, 3-(methylamino)-pyrrolidino, 3-(dimethylamino)- pyrrolidino, 2-(hydroxymethyl)-pyrrolidino, 2- (dimethylaminocarbonyl) -pyrrolidino or 3,4-dihydroxy-pyrrolidino.
  • Embodiment 154 A compound according to embodiment 149, wherein
  • NR h R k is piperazino, 4-methylpiperazino, 4-(methylsulfonyl)-piperazino, or 4- (dime thylaminosulfonyl) - pip er azino .
  • Embodiment 155 A compound according to embodiment 149, wherein
  • NR h R k is piperidino, 3-hydroxypiperidino, 4- hy dr oxyp ip e ridino , 2- (hydroxymethyl)-piperidino, 3-(hydroxymethyl)-piperidino, 4- (hydroxymethyl) -piperidino, 3-methoxy-piperidino, 4-(methoxymethyl)- piperidino, 4-(fluoromethyl)-piperidino, 4-(trifluoromethyl)-piperidino, 4-cyano-piperidino, 4-carbamoyl-piperidino, 4-(methylamino)- piperidino, 4-(dimethylamino)-piperidino, 4-(methylaminomethyl)- piperidino, or 4- (dimethylaminome thy 1) -piperidino.
  • Embodiment 156 A compound according to embodiment 149, wherein
  • NR h R k is NHR k , where R k is 2-hydroxypropyl, 2-(methylsulfonyl)-ethyl,
  • Embodiment 157 A compound according to embodiment 149, wherein
  • NR h R k is N(CHa)R k , where R k is 2-hydroxyethyl, tetrahydropyran-4-yl,
  • Embodiment 158 A compound according to embodiment 149, wherein
  • NR h R k is N(CH 2 CH 2 OH)2.
  • Embodiment 159 A compound according to embodiment 148, wherein
  • G is -(CH 2 ) 2 - 3 -C(0)-N(CH 3 ) 2 .
  • Embodiment 160 A compound according to embodiment 148, wherein
  • G is -(CH 2 ) 3 -C(0)-(4-methylpiperazino).
  • Embodiment 161 A compound according to embodiment 148, wherein
  • G is -CH(CH 3 )-C(0)-NR h R k , where NR h R k is methylamino, dimethylamino, 4-methylpiperazino, or morpholino.
  • Embodiment 162 A compound according to embodiment 148, wherein
  • G is -C(CH 3 ) 2 -C(0)-N(CH 3 ) 2 .
  • Embodiment 163 A compound according to embodiment 134, wherein G is -CH-[C(0)-N(CH 3 ) 2 ]-[CH 2 0H], -CH-[C(0)-N(CH 3 ) 2 ]-[(CH 2 ) 4 -NH 2 ], or -CH- [C(0)-N(CH 3 ) 2 ]-[(CH 2 ) 4 -N(CH 3 ) 2 ].
  • Embodiment 164 A compound according to embodiment 134, wherein
  • G is -Ci- 8 alkyl substituted once by -0-R h .
  • Embodiment 165 A compound according to embodiment 164, wherein
  • G is -(CH 2 ) 2 -0-R h .
  • Embodiment 166 A compound according to embodiment 165, wherein
  • R h is hydrogen, methyl, or ethyl.
  • Embodiment 167 A compound according to embodiment 165, wherein
  • R h is trifluoromethyl, 2-fluoroethyl, 3-fluoropropyl, or 2,2-difluoroethyl.
  • Embodiment 168 A compound according to embodiment 165, wherein
  • R h is tetrahydrofuran-2-ylmethyl.
  • Embodiment 169 A compound according to embodiment 165, wherein
  • R h is 2-hydroxyethyl
  • Embodiment 170 A compound according to embodiment 165, wherein
  • R h is 3-hydroxypropyl
  • Embodiment 171 A compound according to embodiment 165, wherein
  • R h is 2-methoxyethyl.
  • Embodiment 172 A compound according to embodiment 165, wherein
  • R h is 2-(2-hydroxyethoxy)-ethyl.
  • Embodiment 173 A compound according to embodiment 165, wherein
  • R h is 2-hydroxypropyl or l-hydroxyprop-2-yl.
  • Embodiment 174 A compound according to embodiment 165, wherein
  • R h is 2-cyanoethyl, 2-(methylcarbonylamino)-ethyl, or 2- (methylsulfonylamino) -ethyl.
  • Embodiment 175 A compound according to embodiment 165, wherein
  • R h is 2-aminoethyl, 2-(methylamino)-ethyl, or 2-(dimethylamino)-ethyl.
  • Embodiment 176 A compound according to embodiment 165, wherein
  • R h is carbamoylmethyl
  • Embodiment 177 A compound according to embodiment 164, wherein G is -(CH 2 ) 3 -0-R h .
  • Embodiment 178 A compound according to embodiment 177, wherein
  • R h is hydrogen, methyl, or ethyl.
  • Embodiment 179 A compound according to embodiment 177, wherein
  • R h is 2-hydroxyethyl
  • Embodiment 180 A compound according to embodiment 164, wherein
  • G is -(CH2) 4 -OH, -(CH2) 5 -0H, -CH 2 C(CH 3 ) 2 -OH, -CH 2 C(CH 3 ) 2 -OCH 3 , -
  • Embodiment 181 A compound according to embodiment 164, wherein
  • G is -CH 2 CH(CH 3 )-0-R h .
  • Embodiment 182 A compound according to embodiment 181, wherein
  • R h is hydrogen, methyl, or ethyl.
  • Embodiment 183 A compound according to embodiment 134, wherein
  • G is -CH 2 -CH(OH)-CH 2 -OH.
  • Embodiment 184 A compound according to embodiment 134, wherein
  • G is -Ci- 8 alkyl substituted once by -NR h R k .
  • Embodiment 185 A compound according to embodiment 184, wherein
  • G is -(CH 2 ) 2 -NR h R k .
  • Embodiment 186 A compound according to embodiment 185, wherein
  • NR h R k is amino, methylamino, or dimethylamino.
  • Embodiment 187 A compound according to embodiment 185, wherein
  • NR h R k is methylcarbonylamino.
  • Embodiment 188 A compound according to embodiment 185, wherein
  • NR h R k is (dimethylamino) methylcarbonylamino
  • Embodiment 189 A compound according to embodiment 185, wherein
  • NR h R k is methylsulfonylamino.
  • Embodiment 190 A compound according to embodiment 185, wherein
  • NR h R k is piperidino, 4-hydroxypiperidino, or 3-hydroxypiperidino.
  • Embodiment 191 A compound according to embodiment 185, wherein
  • NR h R k is piperidino, 4,4-difluoropiperidino, or 3,3-difluoropiperidino.
  • Embodiment 192 A compound according to embodiment 185, wherein
  • NR h R k is 2-oxo-pyrrolidino, 2-oxo-imidazolidino, or 3-oxo-piperazino.
  • Embodiment 193 A compound according to embodiment 185, wherein
  • NR h R k is piperazino, 4-methylpiperazino, morpholino, or 1, 1-dioxo- thiomorpholino.
  • Embodiment 194 A compound according to embodiment 184, wherein
  • G is -(CH 2 ) 3 -NR h R k .
  • Embodiment 195 A compound according to embodiment 194, wherein
  • NR h R k is amino, dimethylamino, or diethylamino.
  • Embodiment 196 A compound according to embodiment 194, wherein
  • NR h R k is piperidino, 4-methylpiperazino, or morpholino.
  • Embodiment 197 A compound according to embodiment 184, wherein
  • G is -(CH 2 ) 4 -NR h R k .
  • Embodiment 198 A compound according to embodiment 197, wherein
  • NR h R k is amino, dimethylamino, or diethylamino.
  • Embodiment 199 A compound according to embodiment 133, wherein
  • G is -Ci- 6 alkylene-heterocyclyl, where the alkylene and heterocyclyl groups are optionally substituted one or more times with substituents independently selected from R c .
  • Embodiment 200 A compound according to embodiment 199, wherein
  • G is -CH 2 -heterocyclyl, where the heterocyclyl group is optionally substituted once with a substituent selected from R c .
  • Embodiment 201 A compound according to embodiment 200, wherein
  • the heterocyclyl group is tetrahydropyran-4-yl, tetrahydrofuran-2-yl, 1,4- dioxan-2-yl, morpholin-2-yl, tetrahydropyran-2-yl, piperidin-4-yl, l-(2- hydroxyethyl)-piperidin-4-yl, l-(dimethylaminomethylcarbonyl)- piperidin-4-yl, piperazin-2-yl, or l-methyl-piperazin-2-yl.
  • Embodiment 202 A compound according to embodiment 133, wherein G is C3- 10 cycloalkyl optionally substituted one or more times with
  • Embodiment 203 A compound according to embodiment 202, wherein
  • G is 4-hydroxy- cyclohexyl, 4- carboxy- cyclohexyl, or 4- (dimethylaminocarbonyl) - cyclohexyl.
  • Embodiment 204 A compound according to embodiment 202, wherein
  • G is 1-carboxy-cyclopropyl, l-(ethoxycarbonyl)-cyclopropyl, or 1- (dimethylamino-carbonyl)-cyclopropyl.
  • Embodiment 205 A compound according to embodiment 133, wherein
  • G is Ci- 6 alkylene-Ca- 10 cycloalkyl, where the alkylene and cycloalkyl groups are optionally substituted one or more times with substituents independently selected from R c .
  • Embodiment 206 A compound according to embodiment 205, wherein
  • G is -CH 2 -(4-hydroxy-cyclohexyl).
  • Embodiment 207 A compound according to embodiment 205, wherein
  • G is -(CH 2 ) 2 -(4-hydroxy-cyclohexyl).
  • Embodiment 208 A compound according to embodiment 205, wherein
  • G is -CH 2 -[4-(hydroxymethyl)-cyclohexyl].
  • Embodiment 209 A compound according to embodiment 133, wherein
  • G is heterocyclyl optionally substituted one or more times with substituents independently selected from R c .
  • Embodiment 210 A compound according to embodiment 209, wherein
  • G is piperidin-4-yl, l-methyl-piperidin-4-yl, l-carboxy-piperidin-4-yl, 1-
  • Embodiment 211 A compound according to embodiment 209, wherein
  • G is piperidin-3-yl or l-(dimethylaminomethylcarbonyl)-piperidin-3-yl.
  • Embodiment 212 A compound according to embodiment 209, wherein
  • Embodiment 213 A compound according to embodiment 209, wherein
  • G is pyrrolidin-3-yl, l-methyl-pyrrolidin-3-yl, l-(2-hydroxyethyl)-pyrrolidin-3- yl, 1 -(2 -hydroxypropyl) -pyrrolidin- 3-yl, 1 - (2 -hydroxy-2 -methylpropyl) - pyrrolidin- 3 -yl, 1- ( 1 -hy droxyethylcarbonyl) -pyrrolidin- 3 -yl, 1- (2- carboxyethyl)-pyrrolidin-3-yl, or l-(2-methylsulfonylamino-ethyl)- pyrrolidin- 3 -yl.
  • Embodiment 214 A compound according to embodiment 134, wherein
  • G is -Ci- 8 alkyl substituted once by -S-R h .
  • Embodiment 215 A compound according to embodiment 214, wherein
  • G is -(CH 2 ) 2 -S-R h .
  • Embodiment 216 A compound according to embodiment 215, wherein
  • R h is methyl or ethyl.
  • Embodiment 217 A compound according to embodiment 215, wherein
  • R h is 2-hydroxyethyl
  • Embodiment 218 A compound according to embodiment 214, wherein
  • G is -(CH 2 ) 3 -S-R h .
  • Embodiment 219 A compound according to embodiment 218, wherein
  • R h is methyl
  • Embodiment 220 A compound according to embodiment 134, wherein
  • G is -Ci- 8 alkyl substituted once by -S0 2 -R h .
  • Embodiment 221 A compound according to embodiment 220, wherein
  • G is -(CH 2 ) 2 -S0 2 -R h .
  • Embodiment 222 A compound according to embodiment 221, wherein
  • R h is methyl or ethyl.
  • Embodiment 223 A compound according to embodiment 221, wherein
  • R h is 2-hydroxyethyl
  • Embodiment 224 A compound according to embodiment 220, wherein
  • G is -(CH 2 ) 3 -S0 2 -R h .
  • Embodiment 225 A compound according to embodiment 224, wherein
  • Embodiment 226 A compound according to embodiment 133 wherein
  • G is -CH(CH3)-NR h R k , where NR h R k is pyrrolidino, piperidino, 4-methyl- piperazino, morpholino, or dimethylamino.
  • Embodiment 227 A compound according to embodiment 133 wherein
  • G is l-(2-hydroxypropyl)-pyrrolodin-3-yl or l-(l-hydroxyethylcarbonyl)- pyrrolidin-3-yl.
  • Embodiment 228 A compound according to embodiment 133 wherein
  • G is l-(dimethylaminomethylcarbonyl)-piperidin-4-yl.
  • Embodiment 229 A compound according to embodiment 133 wherein
  • G is -(CH 2 ) 3 -5-0H.
  • Embodiment 230 A compound according to embodiment 133 wherein
  • G is 4-hydroxy- cyclohexylmethyl.
  • Embodiment 231 A compound according to embodiment 133 wherein
  • G is -(CH 2 ) 2 -NHC(0)-CH 2 -N(CH 3 ) 2 .
  • Embodiment 232 A compound according to embodiment 133 wherein
  • G is 4-hydroxy- cyclohexylmethyl.
  • Embodiment 233 A compound according to embodiment 133 wherein
  • G is -CH 2 -C(0)-NR h R k where NR h R k is 3-hydroxy-pyrrolidino or 3-(dimethyl- amino) -pyrrolidino.
  • Embodiment 234 A compound according to embodiment 133 wherein
  • G is -CH 2 -C(0)-NR h R k where NR h R k is morpholino.
  • Embodiment 235 A compound according to embodiment 133 wherein
  • G is -CH 2 -C(0)-NR h R k where NR h R k is 4-hydroxy-piperidino, 4-methoxy- piperidino, 4-(hydroxymethyl)-piperidino, 3-hydroxy-piperidino, 3-methoxy- piperidino, 3-(hydroxymethyl)-piperidino, or 4,4-difluoropiperidino.
  • Embodiment 236 A compound according to embodiment 133 wherein
  • G is -CH 2 -C(0)-NR h R k where NR h R k is dimethylamino.
  • Embodiment 237 A compound according to embodiment 133 wherein
  • G is -(CH 2 ) 2 -0-(CH 2 ) 2 -0H.
  • Embodiment 238 A compound according to embodiment 133 wherein G is -(CH 2 )2-0-(CH 2 )2-0CH 3 .
  • Embodiment 239 A compound according to embodiment 133 wherein
  • G is -CH 2 -CH(CH 3 )-OH.
  • Embodiment 240 A compound according to any one of embodiments 66 to 112, wherein
  • L is C(0)NH
  • G is Ci- 8 alkyl substituted once by a heteroaryl group, where the heteroaryl group is optionally substituted one or more times with substituents independently selected from R x .
  • Embodiment 241 A compound according to embodiment 240, wherein
  • G is -CH 2 -(2-furyl), -CH 2 -(2-thienyl), -CH 2 -(2-oxazolyl), or -CH 2 -(2- thiazolyl).
  • Embodiment 242 A compound according to embodiment 240, wherein
  • G is -(CH 2 ) 2 -3-(l-pyrrolyl), -(CH 2 ) 2 - 3 -(l-pyrazolyl), or -(CH 2 ) 2 - 3 -(l- imidazolyl).
  • Embodiment 243 A compound according to any one of embodiments 66 to 112, wherein
  • L is C(0)NH
  • G is Ci- 8 alkyl substituted once by a phenyl group, where the phenyl group is optionally substituted one or more times with substituents independently selected from R x .
  • Embodiment 244 A compound according to embodiment 243, wherein
  • G is -(-CH 2 )i- 2 -(4-hydroxyphenyl) or -(-CH 2 )i- 2 -(4-methoxy-3- hydroxyphenyl) .
  • Embodiment 245 A compound according to any one of embodiments 66 to 112, wherein
  • L is C(0)NH
  • G is -CH 2 -C(0)NH-CH 2 -(4-hydroxyphenyl).
  • Embodiment 246 A compound according to any one of embodiments 66 to 112, wherein
  • L is C(0)NH
  • G is -CH 2 -C(0)-[4-(pyrimidin-2-yloxy)-piperidino]
  • Embodiment 247 A compound according to any one of embodiments 1 to 246,
  • Embodiment 248 A compound according to any one of embodiments 1 to 247, wherein the compound is in the form of a free acid or a free base.
  • Embodiment 249 A compound according to any one of embodiments 1 to 247, wherein the compound is in the form of a pharmaceutically acceptable salt.
  • Embodiment 250 A compound according to embodiment 1, wherein the compound is a compound from Table A or a pharmaceutically acceptable salt thereof.
  • Compounds 1-474 in Table A may be prepared as described in WO '018 or other methods apparent to one of skill in the art.
  • Compounds 473 and 474 in Table A may be prepared as described in the Examples section below.
  • the present invention provides a pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in treating sickle cell disease or related disorders.
  • the present invention provides a pharmaceutical composition comprising a compound (or salt) of any one of embodiments 1 to 250 (recited above) and a pharmaceutical carrier.
  • the pharmaceutical composition comprises a compound (or salt) of any one of the examples and a pharmaceutically acceptable carrier.
  • the invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • the invention provides a pharmaceutical composition comprising a compound (or salt) of any one of embodiments 1 to 250 and a pharmaceutical acceptable carrier.
  • the present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in medicine.
  • the invention provides a compound (or salt) of any one of embodiments 1 to 250 for use in medicine.
  • the present invention further provides for the use of a compound of
  • the invention also provides for the use of a compound (or salt) of any one of embodiments 1 to 250 in combination with one or more medically effective active compounds for simultaneous, subsequent, or sequential
  • the invention provides a pharmaceutical composition comprising a compound (or salt) of any one of embodiments 1 to 250 and at least one other medically effective active ingredient selected from HU, Nrf2 activators, antioxidants, detoxification agents, and anti-inflammatory agents.
  • the invention provides for the use of a compound (or salt) of any one of embodiments 1 to 250 in combination with at least one other medically effective active ingredient selected from Nrf2 activators, antioxidants, detoxification agents, and anti-inflammatory agents for simultaneous, subsequent, or sequential administration.
  • Nrf2 Activators may comprise a Michael addition acceptor, one or more fumaric acid esters, i.e. fumaric acid mono- and/or diesters which may be selected from the group of monoalkyl hydrogen fumarate and dialkyl fumarate, such as monomethyl hydrogen fumarate, dimethyl fumarate, monoethyl hydrogen fumarate, and diethyl fumarate, furthermore ethacrynic acid, bardoxolone methyl (methyl 2- cyano-3, 12-dioxooleana- 1,9(1 l)dien-28-oate), isothiocyanate such as sulforaphane, l,2-dithiole-3-thione such as oltipraz, 3,5-di-tert-butyl-4-hydroxytoluene, 3- hydroxycoumarin, or a pharmacologically active derivative or analog of the aforementioned agents.
  • fumaric acid esters i.e. fumaric acid mono- and
  • Nrf2 Activators compounds may be classified based on their chemical structures: Diphenols, Michael reaction acceptors, isothiocyanates, thiocarbamates, trivalent arsenicals, l,2-dithiole-3-thiones, hydroperoxides, vicinal dimercaptans, heavy metals, and polyenes.
  • Nrf2 Activators are chemically reactive in that they may be electrophiles, substrates for glutathione transferases, and/or can modify sulfhydryl groups by alkylation, oxidation, or reduction.
  • the Nrf2 activators are bardoxolone methyl and dialkyl fumarate such as dimethyl fumarate and diethyl fumarate.
  • Nrf2 activators are selected from: Chalcone derivatives such as 2-trifluoromethyl-2'-methoxychalcone, auranofin, ebselen, 1,2- naphthoquinone, cynnamic aldehyde, caffeic acid and its esters, curcumin, reservatrol, artesunate, tert-butylhydroquinone, and -quinone, (tBHQ, tBQ), vitamins Kl, K2 and K3, menadione, fumaric acid esters, i.e.
  • Chalcone derivatives such as 2-trifluoromethyl-2'-methoxychalcone, auranofin, ebselen, 1,2- naphthoquinone, cynnamic aldehyde, caffeic acid and its esters, curcumin, reservatrol, artesunate, tert-butylhydroquinone, and -quinone,
  • fumaric acid mono- and/or diester which may be selected from the group of monoalkyl hydrogen fumarate and dialkyl fumarate, such as monomethyl hydrogen fumarate, dimethyl fumarate (DMF), monoethyl hydrogen fumarate, and diethyl fumarate, 2- cyclopentenones, ethacrynic acid and its alkyl esters, bardoxolone methyl (methyl 2- cyano-3, 12-dioxooleana- 1,9(1 l)dien-28-oate) (CDDO-Me, RTA 402), ethyl 2-cyano- 3, 12-dioxooleana- 1,9(1 l)dien-28-oate, 2-cyano-3, 12-dioxooleana- 1,9(1 l)dien-28-oic acid (CDDO), l[2-Cyano-3, 12-dioxooleana- 1,9(1 l)-dien-28-
  • allylisothiocyanate 6-methylthiohexyl isothiocyanate, 7-methylthioheptyl isothiocyanate, sulforaphane, 8-methylthiooctyl isothiocyanate, corticosteroids, such as dexamethasone, 8-iso prostaglandin A2, alkyl pyruvate, such as methyl and ethyl pyruvate, diethyl or dimethyl oxaloproprionate, 2-acetamidoacrylate, methyl or ethyl-2-acetamidoacrylate, hypoestoxide, parthenolide, eriodictyol, 4-hydroxy-2- nonenal, 4-oxo-2nonenal, geranial, zerumbone, aurone, isoliquiritigenin,
  • Nrf2 activators are selected from: carnosic acid, 2- naphthoquinone, cynnamic aldehyde, caffeic acid and its esters, curcumin, reservatrol, artesunate, tert-butylhydroquinone, vitamins Kl, K2 and K3, fumaric acid esters, i.e. fumaric acid mono- and/or diester which is preferably selected from the group of monoalkyl hydrogen fumarate and dialkyl fumarate, such as
  • isothiocyanate such as sulforaphane, l,2-dithiole-3-thione such as oltipraz, 3,5-di-tert-butyl-4-hydroxytoluene, 3-hydroxycoumarin, 4- hydroxynonenal, 4-oxononenal, malondialdehyde, (E)-2-hexenal, capsaicin, allicin, allylisothiocyanate, 6-methylthiohexyl isothiocyanate, 7-methylthioheptyl isothiocyanate, sulforaphane, 8-methylthiooctyl isothiocyanate, 8-iso prostaglandin A2, alkyl pyruvate, such as methyl and ethyl pyruvate, diethyl or dimethyl oxaloproprionate, 2-
  • Nrf2 Activators may be Michael reaction acceptors such as dimethylfumarate, monomethyl hydrogen fumarate isothiocyanates and l,2-dithiole-3-thiones.
  • Nrf2 Activators are selected from monomethyl hydrogen fumarate, dimethyl fumarate, oltipraz, 1,2-naphthoquinone, tert-butylhydroquinone, methyl or ethyl pyruvate, 3,5-di-tert-butyl-4- hy dr oxy toluene, diethyl and dimethyl oxaloproprionate, hypoestoxide, parthenolide, eriodictyol, 4-Hydroxy-2-nonenal, 4-oxo-2nonenal, geranial, zerumbone, aurone, isoliquiritigenin, xanthohumol, [10]-Shogaol, eugeno
  • antioxidants examples include vitamin C, vitamin E, carotenoids, retinoids, polyphenols, flavonoids, lignan, selenium, butylated hydroxyanisole, ethylene diamine tetra-acetate, calcium disodium, acetylcysteine, probucol, and tempo.
  • Examples of the detoxification agents include dimethyl caprol, glutathione, acetylcysteine, methionine, sodium hydrogen carbonate, deferoxamine mesylate, calcium disodium edetate, trientine hydrochloride, penicillamine, and
  • the anti-inflammatory agents include steroidal anti-inflammatory agents and non-steroidal anti-inflammatory agents.
  • steroidal anti-inflammatory agents include cortisone acetate, hydrocortisone, paramethasone acetate, prednisolone, prednisolone, methylprednine, dexamethasone,
  • inflammatory agents include salicylic acid non-steroidal anti-inflammatory agents such as aspirin, difiunisal, aspirin+ascorbic acid, and aspirin dialuminate; aryl acid non-steroidal anti-inflammatory agents such as diclofenac sodium, sulindac, fenbufen, indomethacin, indomethacin farnesyl, acemetacin, proglumetacin maleate, anfenac sodium, nabmeton, mofezolac, and etodorag; fenamic acid non- steroidal anti-inflammatory agents such as mefenamic acid, flufenamic acid aluminum, tolfenamic acid, and floctafenine; propionic acid non-steroidal anti inflammatory agents such as ibuprofen, flurbiprofen, ketoprofen, naproxen, pranoprofen, fenoprofen calcium, thiaprofen, oxapro
  • sequential administration includes the co-administration of one or more additional active agents within a period of one week, 72 hours, 48 hours, 24 hours, or 12 hours.
  • compositions disclosed herein are co-administered in combination with one or more additional active agents for treatment of sickle cell disease, beta-thalassemia, or a related disorder.
  • additional active agents may include, but are not limited to, folic acid, penicillin or another antibiotics, preferably a quinolone or macrolide, antivirals, anti-malarial prophylactics, and analgesics to control pain crises.
  • compositions are co-administered with one or more additional agents that increase expression of HbF, for example, hydroxyurea (HU).
  • additional agents that increase expression of HbF for example, hydroxyurea (HU).
  • compositions are co-administered with one or more additional treatment protocols, for example, transfusion therapy, stem cell therapy, gene therapy, bone marrow transplants, dialysis or kidney transplant for kidney disease, gallbladder removal in people with gallstone disease, hip replacement for avascular necrosis of the hip, surgery for eye problems, and wound care for leg ulcers.
  • additional treatment protocols for example, transfusion therapy, stem cell therapy, gene therapy, bone marrow transplants, dialysis or kidney transplant for kidney disease, gallbladder removal in people with gallstone disease, hip replacement for avascular necrosis of the hip, surgery for eye problems, and wound care for leg ulcers.
  • compositions are administered in an amount effective to induce a pharmacological, physiological, or molecular effect compared to a control that is not administered the composition.
  • compositions are administered to a subject in need thereof to increase expression of HbF in the subject.
  • Suitable controls are known in the art and can be determined based on the disease to be treated. Suitable controls include, but are not limited to a subject, or subjects without sickle cell disease, a beta-thalassemia, or a sickle cell related disorder; or a condition or status of a subject with the disease or disorder prior to initiation of the treatment.
  • the selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment desired. Generally dosage levels of 0.001 to 100 mg/kg of body weight daily are administered to mammals. Generally, for intravenous injection or infusion, dosage may be lower.
  • An appropriate dose of a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the present invention may be determined according to any one of several well-established protocols. For example, animal studies such as studies using mice, rats, dogs, and/or monkeys may be used to determine an appropriate dose of a pharmaceutical compound. Results from animal studies may be extrapolated to determine doses for use in other species, such as for example, humans.
  • a compound of Formula (I) or a pharmaceutically acceptable salt thereof may be administered in a daily dosage of between 0.1 mg and 15 mg per kg. In another embodiment, where the subject is a human the daily dose may be between 1 mg and 1000 mg. In another embodiment, a compound of Formula (I) or a pharmaceutically acceptable salt thereof is administered in an amount from 10 mg/day to 1000 mg/day, or from 25 mg/day to 800 mg/day, or from 37 mg/day to 750 mg/day, or from 75 mg/day to 700 mg/day, or from 100 mg/day to 600 mg/day, or from 150 mg/day to 500 mg/day, or from 200 mg/day to 400 mg/day. In other embodiments, the previous daily periods of administration of an amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof may be changed to a period of every 6 hours, 12 hours, 48 hours, 72 hours, 96 hours, 1 week, or 2 weeks.
  • compositions comprising a fumaric acid ester such as DMF, MMF, or a combination thereof
  • daily dosages for fumaric acid esters in a human can range from about 1 mg to about 5,000 mg, from about 10 mg to about 2,500 grams, or from about 50 mg to about 2,000 grams of a fumaric acid ester, or a pharmacologically active salt thereof.
  • an effective dose of DMF or MMF to be administered to a subject can be from about 0.1 g to about 1 g or more than 1 g per day; from about 200 mg to about 800 mg per day; from about 240 mg to about 720 mg per day; from about 480 mg to about 720 mg per day; or about 720 mg per day.
  • the daily dose can be administered in separate administrations of 2, 3, 4, or 6 equal doses.
  • the one or more fumaric acid esters, or pharmacologically active salts, derivatives, analogues or prodrugs thereof are present in a pharmaceutical preparation.
  • the composition is administered to the patient three times per day (TID).
  • the pharmaceutical preparation is administered to the patient two times per day (BID).
  • the composition is administered at least one hour before or after food is consumed by the patient.
  • the composition is administered as part of a dosing regimen.
  • the patient can be administered a first dose of the
  • composition for a first dosing period comprising: a second dose of the composition for a second dosing period, optionally followed by one or more additional doses for one or more additional dosing periods.
  • the first dosing period can be less than one week, one week, or more than one week.
  • the dosage regime is a dose escalating dosage regime.
  • the first dose can be a low dose, followed by measurement of levels of HbF expression, and then the step of decreasing, maintaining, or increasing the dose.
  • the current labeled dosing of hydroxyurea for sickle cell disease calls for the administration of an initial dose of 15 mg/kg/day in the form of a single dose, with monitoring of the patient's blood count every 2 weeks. If the blood counts are in an acceptable range, the dose may be increased by 5 mg/kg/day every 12 weeks until the MTD of 35 mg/kg/day is reached.
  • Pharmaceutical compositions can contain 1 mg/kg to 50 mg/kg of a fumaric acid ester, such as MMF, in combination with 1 mg/kg to 35 mg/kg of HU.
  • the combination formulation can contain 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 mg/kg of HU.
  • compositions comprising a compound of the invention are disclosed.
  • the pharmaceutical compositions may be for administration by oral, parenteral (intramuscular, intraperitoneal, intravenous (IV) or subcutaneous injection), transdermal (either passively or using iontophoresis or electroporation), or transmucosal (nasal, vaginal, rectal, or sublingual) routes of administration or using bioerodible inserts and can be formulated in unit dosage forms appropriate for each route of administration.
  • Red blood cells which are cells of erythroid lineage, are the primary producers of hemoglobin. Therefore, in an embodiment a compound of the invention or a pharmaceutical composition is administered to a subject in an effective amount to induce HbF in hematopoietic stems cells. Therefore, in some embodiments, a compound of the invention or a pharmaceutical composition is administered in an effective amount to induce HbF expression in cells of erythroid lineage in the bone marrow (i.e., the red bone marrow), the liver, the spleen, or combinations thereof.
  • the bone marrow i.e., the red bone marrow
  • a compound of the invention or a pharmaceutical composition induces HbF in cells synthesizing or committed to synthesize
  • a compound of the invention induces HbF in basophilic normoblast/early normoblast also commonly called erythroblast, polychromatophilic normoblast/intermediate normoblast,
  • a compound of the invention or a pharmaceutical composition is administered locally, to the site in need of therapy.
  • red blood cells are the primary producers of hemoglobin
  • other, non-hematopoietic cells including macrophage, retinal pigment cells, and alveolar epithelial cells such as alveolar type II (ATII) cells and Clara cells may also synthesize hemoglobin.
  • ATII alveolar type II
  • a compound of the invention or a pharmaceutical composition is administered locally to interfaces where oxygen-carbon dioxide diffusion occurs, including but not limited, to the eye or lungs.
  • a compound of the invention or a pharmaceutical composition is administered locally to the eye to treat a retinopathy, or another ocular manifestation associated with sickle cell disease or a related disorder.
  • the pharmaceutical compositions are formulated for oral delivery.
  • Oral solid dosage forms are described generahy in Remington's
  • Solid dosage forms include tablets, capsules, pills, troches or lozenges, cachets, pellets, powders, or granules or incorporation of the material into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc., or into liposomes.
  • Such compositions may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the disclosed.
  • the compositions may be prepared in liquid form, or may be in dried powder (e.g., lyophilized) form.
  • liquid dosage forms for oral administration including pharmaceutically acceptable emulsions, solutions, suspensions, and syrups, which may contain other components including inert diluents; adjuvants such as wetting agents, emulsifying and suspending agents; and sweetening, flavoring, and perfuming agents.
  • pharmaceutically acceptable emulsions, solutions, suspensions, and syrups which may contain other components including inert diluents; adjuvants such as wetting agents, emulsifying and suspending agents; and sweetening, flavoring, and perfuming agents.
  • Controlled release oral formulations may be desirable.
  • Compounds of the invention can be incorporated into an inert matrix which permits release by either diffusion or leaching mechanisms, e.g., gums.
  • Slowly degenerating matrices may also be incorporated into the formulation.
  • the location of release may be the stomach, the small intestine (the duodenum, the jejunem, or the ileum), or the large intestine.
  • the methods of treatment disclosed herein can include a first step of selecting a subject for treatment.
  • the subject is selected for treatment when the subject exhibits one or more of the clinical symptoms of sickle cell disease, beta-thalassemia, or a related disorder such as those discussed above.
  • the subject is selected for treatment when the subject exhibits a genetic or biochemical indicator of sickle cell disease, beta-thalassemia, or a related disorder.
  • the subject can be selected for treatment based on
  • the subject is selected when a combination of chnical symptoms and genetic or biochemical alterations are identified.
  • the subject is selected based on one or more clinical symptoms, or one or more genetic or biochemical alterations.
  • subjects can be selected for treatment based on the identification of a genetic alteration, a biochemical or morphological alteration, or a combination thereof, before the subject exhibits clinical symptoms of sickle cell disease, beta-thalassemia, or a related disorder.
  • the methods of treatment may further comprise the step of determining whether a subject is at risk for or has sickle cell disease, beta- thalassemia, or a related disorder by obtaining or having obtained a biological sample from the subject and performing or having performed a bodily fluid test on the biological sample to determine if the subject has one or more biomarkers or a genetic mutation associated with sickle cell disease, beta-thalassemia, or a related disorder. If the subject is determined to be at risk for or has sickle cell disease, beta-thalassemia, or a related disorder, the method further comprises
  • the method may further comprise obtaining or having obtained biological samples over a period of time from the subject and performing or having performed a bodily fluid test on the biological samples to determine whether the level of one or more biochemical markers are increasing or decreasing, and if the level of one or more biochemical markers are not trending in the desired direction then administering a greater dose of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the ratio of HbF to HbS in a sample may be measured and a pronounced increase in the amount of HbF to HbS in a second sample relative to a first sample from a subject indicates that the dosage of a Formula (I) or a pharmaceutically acceptable salt thereof is a therapeutically effective dosage.
  • no change or no significant change in the amount of HbF to HbS in a second sample relative to a first sample from a subject may indicate that the dosage of a Formula (I) or a pharmaceutically acceptable salt thereof is not a therapeutically effective dosage and that the dosage may need to be increased.
  • a compound of Formula (I) or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof in an amount to decrease the level of one or more biomarker markers such as CRP or ROS.
  • the period between collection of biological samples may be 1 week, 2 weeks,
  • the subject is selected for treatment based on identification of one or more genetic alterations in one or more alleles of the human beta-globin gene or expression control sequence thereof.
  • Genetic alterations indicative of sickle cell disease, beta-thalassemia, or related disorders include the exemplary mutations discussed above, or other mutations that lead to a reduction in the synthesis, structure, or function of human beta-globin protein.
  • Methods of selecting a subject having one or more genetic alterations in one or more alleles of the beta-globin gene or expression control sequences thereof include the steps of obtaining a biological sample and detecting the presence or absence one or more genetic alterations.
  • the biological sample obtained contains nucleic acid from the subject and the step of detecting detects the presence or absence one or more genetic alterations in one or more alleles of the beta-globin gene or expression control sequences thereof in the biological sample.
  • Any biological sample that contains the DNA of the subject to be diagnosed can be employed, including tissue samples and blood samples, with nucleated blood cells being a particularly convenient source.
  • the DNA may be isolated from the biological sample prior to testing the DNA for the presence or absence of the genetic alterations.
  • the detecting step can include determining whether the subject is
  • the step of detecting the presence or absence of the genetic alteration can include the step of detecting the presence or absence of the alteration in both chromosomes of the subject (i.e., detecting the presence or absence of one or two alleles containing the marker or functional polymorphism). More than one copy of a genetic alterations (i.e., subjects homozygous for the genetic marker) can indicate a greater risk of developing sickle cell disease, beta-thalassemia, or related disorder.
  • the subject is heterozygous for two or more genetic alterations in the beta-globin gene (also referred to herein as double heterozygotes, triple heterozygotes, etc.).
  • One copy of two or more genetic alterations in the beta-globin gene can indicate a greater risk of developing sickle cell disease, beta-thalassemia, or related disorder.
  • the process of determining the genetic sequence of human beta-globin gene is referred to as genotyping.
  • the human beta-globin gene is sequenced.
  • Methods for amplifying DNA fragments and sequencing them are well known in the art.
  • automated sequencing procedures that can be utilized to sequence the beta-globin gene, include, but not limited to, sequencing by mass spectrometry single-molecule real-time sequencing, ion semiconductor (ion torrent sequencing), pyrosequencing (454), sequencing by synthesis, sequencing by ligation, chain termination (Sanger sequencing).
  • the genotype of the subject is determined by
  • SNP genotyping can include the steps of collecting a biological sample from a subject (e.g., sample of tissues, cells, fluids, secretions, etc.), isolating genomic DNA from the cells of the sample, contacting the nucleic acids with one or more primers which specifically hybridize to a region of the isolated nucleic acid containing a target SNP under conditions such that hybridization and amplification of the target nucleic acid region occurs, and determining the nucleotide present at the SNP position of interest, or, in some assays, detecting the presence or absence of an amplification product (assays can be designed so that hybridization and/or amplification will only occur if a particular SNP allele is present or absent). In some assays, the size of the amplification product is detected and
  • the neighboring sequence can be used to design SNP detection reagents such as oligonucleotide probes and primers.
  • SNP genotyping methods include, but are not limited to, TaqMan assays, molecular beacon assays, nucleic acid arrays, allele-specific primer extension, allele-specific PCR, arrayed primer extension, homogeneous primer extension assays, primer extension with detection by mass spectrometry, pyrosequencing, multiplex primer extension sorted on genetic arrays, ligation with rolling circle amplification, homogeneous ligation, multiplex ligation reaction sorted on genetic arrays, restriction-fragment length polymorphism, single base extension-tag assays, and the Invader assay.
  • Such methods may be used in combination with detection mechanisms such as, for example, luminescence or chemiluminescence detection, fluorescence detection, time-resolved fluorescence detection, fluorescence resonance energy transfer, fluorescence polarization, mass spectrometry, and electrical detection.
  • detection mechanisms such as, for example, luminescence or chemiluminescence detection, fluorescence detection, time-resolved fluorescence detection, fluorescence resonance energy transfer, fluorescence polarization, mass spectrometry, and electrical detection.
  • Suitable methods for detecting polymorphisms include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes, comparison of the electrophoretic mobility of variant and wild type nucleic acid molecules, and assaying the movement of polymorphic or wild-type fragments in polyacrylamide gels containing a gradient of denaturant using denaturing gradient gel electrophoresis (DGGE). Sequence variations at specific locations can also be assessed by nuclease protection assays such as Rnase and S 1 protection or chemical cleavage methods.
  • DGGE denaturing gradient gel electrophoresis
  • SNPs Another method for genotyping SNPs is the use of two oligonucleotide probes in an oligonucleotide ligation assay (OLA).
  • OLA oligonucleotide ligation assay
  • Other methods that can be used to genotype the SNPs include single-strand conformational polymorphism (SSCP).
  • subjects are selected for treatment based on
  • the methods typically include identifying one or more biochemical or morphological alterations that is/are associated with a genetic alteration in the human beta-globin gene, or otherwise diagnostic of sickle cell disease, a beta-thalassemia, or a related disorder.
  • Methods of diagnosing sickle cell disease, beta-thalassemia, or a related disorder according to biochemical or morphological alterations in the hemoglobin or hemoglobin synthesizing cells are known in the art, and include but are not limited to, analysis of erythrocyte morphology, osmotic fragility, hemoglobin composition, globin synthesis rates, and red blood cell indices.
  • the method includes first testing a subject's blood for HbS, and selecting the subject for treatment if HbS is present.
  • Methods for testing a subject's blood for the presence of HbS include solubility tests (e.g., SICKLEDEX) and sickling test.
  • SICKLEDEX solubility tests
  • a sickling test can be used to determine if a red blood cell changes into a sickle shape after a blood sample is mixed with a reducing agent and identifying morphological changes to shape of red blood cells (i.e., "sickling") by microscopy. Shape change of red blood cells may also be analyzed for shape change using a flow cytometer such as the Amnis
  • ImageStreamX Mark II Imaging Flow Cytometer (MilliporeSigma). Shape change of red blood cells may be quantitated using a software program such as IDEAS application software (MilliporeSigma) using a modified protocol as described in “Imaging flow cytometry for automated detection of hypoxia-induced erythrocyte shape change in sickle cell disease.” van Beers EJ, et al. Am J Hematol.
  • hemoglobin electrophoresis which employs gel electrophoretic techniques to separate out the various types of hemoglobin from a blood sample obtained from the subject.
  • the test can detect abnormal levels of HbS, as well as other abnormal hemoglobins, such as hemoglobin C. It can also be used to determine whether there is a deficiency of any normal form of hemoglobin, as in various thalassemias.
  • Alternatives to electrophoretic techniques include isoelectric focusing and chromatographic techniques.
  • Other tests that can be used to select a subject for treatment with the compositions and methods disclosed herein include tests typically employed as part of a hemoglobinopathy screen, for example, a complete blood count (CBC) or iron study (ferritin). For example, a blood count can be used to detect anemia, and a blood smear and be used to identify sickled cells.
  • CBC complete blood count
  • iron study iron study
  • the resulting mixture is poured into water to precipitate the product.
  • the precipitate may be filtered and dried to give the product, which may not be purified further before use in the next step.
  • the product may be isolated after filtration either with subsequent washings with water and DCM/methanol or through silica gel chromatography using hexanes/ethyl acetate (from 80:20 to 60:40) as an eluent system.
  • 6-Methylamino-5-nitro-nicotinic acid methyl ester (5.0 g) was prepared by following General Procedure A starting from 6-chloro-5-nitro-nicotinic acid methyl ester (5.0 g) and methylamine (33% in EtOH, 24 mL) in THF (150 mL). The crude product was used in the next step without further purification.
  • 5-Amino-6-methylamino-nicotinic acid methyl ester (4.8 g) was prepared by following General Procedure B starting from 6-methylamino-5-nitro-nicotinic acid methyl ester (5.0 g) and Pd/C (20% by weight, 1.0 g) in methanoLTHF (1: 1, 50 mL). The crude product was used in the next step without further purification.
  • Methyl 3-methyl-2- [[6-(trifluoromethyl)- l,3-benzothiazol-2- yl]amino]imidazo[4,5-b]pyridine-6-carboxylate (5.0 g) was prepared by following General Procedure C starting from 6-(trifluoromethyl)-l,3-benzothiazol-2-amine (5.0 g), 5-amino-6-methylamino-nicotinic acid methyl ester (5.0 g), 1, l'-thiocarbonyl- diimidazole (5.0 g), and EDAC (4.5 g) . The crude product was used in next step without further purification.
  • Membranes are blocked in 5% dry milk containing TBS-T for 30 minutes followed by one hour and incubated with HbF or actin antibodies. After several washes, membranes are incubated with 1: 10000 diluted HRP- conjugated secondary antibody (Thermo Scientific), developed with ECL Prime reagent (GE Healthcare Bio-sciences).
  • Images may be captured on a Bio-Rad Chemi-Doc MP Imaging System and protein bands quantified by densitometry.
  • KU812 a human leukemic cell line that expresses the fetal gamma-globin and adult beta-globin genes, was used as a system for screening. KU812 cells have comparable globin gene response patterns as primary erythroid cells after treatments with potential HbF inducers. (See Zein S, Lou RF, Sivanand S,
  • KU812 cells were grown in Iscove’s Modified Dulbecco Media (IMDM) and 10% fetal bovine serum until in log phase growth.
  • IMDM Modified Dulbecco Media
  • KU812 cells in log growth phase were treated with compounds 73, 134, 473 and 236 (See Table A) at a doses of 0.5, 2.5, 5.0 and 20 pM for 48 hours. At harvest, cell counts and viability were measured by 0.4% Trypan blue exclusion. See
  • FIGs 1A-1D Compounds 134 and 473 had minimal effects on cell growth rates and viability remained >90% at the widest range of drug concentrations (See Figures IB and 1C, respectively).
  • sickle erythroid progenitor cells were cultured for 10 days and then treated with Compound 473 for 48 hours at concentrations of 0.5 pM and 2.5 pM.
  • Treated cells were analyzed by western blot for levels of expression of HbF, HbS, and 6-actin relative to cells treated with DMSO, hemin, or HU.
  • the same treated cells were also analyzed by flow cytometry for g-globin gene expression relative to cells treated with DMSO, hemin, or HU.
  • Compound 473 (0.5 pM and 2.5 pM) induced g-globin gene expression by 1.6 and 1.9 fold, respectively, without affecting HbS protein levels. See Figure 3A. Increased F-cell levels were observed by flow cytometry. See Figure 3B.
  • Anti-sickling activity was observed in treated cells under hypoxia conditions.
  • sickle erythroid progenitor cells were cultured for 10 days and then treated with Compound 473 for 48 hours at concentrations of 0.5 pM and 2.5 pM or with hemin (about 50 pM) or with HU (about 100 pM). Treated cells were then subjected to hypoxia conditions (1% O2 and 5% CO2). Cells treated with Compound 473 at concentrations of 0.5 pM and 2.5 pM significantly decreased the percent of sickled cells compared to DMSO control. See Figures 4A and 4B.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des procédés de traitement de la drépanocytose et des complications associées à l'aide des composés de formule (I) et des compositions pharmaceutiques de ceux-ci, soit seuls, soit en combinaison avec d'autres agents actifs.
EP20741695.9A 2019-01-18 2020-01-15 Dérivés d'imidazole fusionnés substitués et procédés de traitement de la drépanocytose et de complications associées Pending EP3911319A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962794293P 2019-01-18 2019-01-18
PCT/US2020/013616 WO2020150306A1 (fr) 2019-01-18 2020-01-15 Dérivés d'imidazole fusionnés substitués et procédés de traitement de la drépanocytose et de complications associées

Publications (2)

Publication Number Publication Date
EP3911319A1 true EP3911319A1 (fr) 2021-11-24
EP3911319A4 EP3911319A4 (fr) 2022-09-21

Family

ID=71613589

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20741695.9A Pending EP3911319A4 (fr) 2019-01-18 2020-01-15 Dérivés d'imidazole fusionnés substitués et procédés de traitement de la drépanocytose et de complications associées

Country Status (9)

Country Link
US (1) US20210338644A1 (fr)
EP (1) EP3911319A4 (fr)
JP (1) JP2022517130A (fr)
KR (1) KR20210129034A (fr)
CN (1) CN113557019A (fr)
AU (1) AU2020209144A1 (fr)
CA (1) CA3127548A1 (fr)
MX (1) MX2021008071A (fr)
WO (1) WO2020150306A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
US8759535B2 (en) * 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
SG182629A1 (en) * 2010-02-18 2012-08-30 High Point Pharmaceuticals Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
WO2012094580A2 (fr) * 2011-01-07 2012-07-12 High Point Pharmaceuticals, Llc Composés capables de moduler le stress oxydatif
JP6564785B2 (ja) * 2014-03-21 2019-08-21 ユニベルシテ パリ−エスト クレテイユ ヴァル ド マルヌＵｎｉｖｅｒｓｉｔｅ Ｐａｒｉｓ−Ｅｓｔ Ｃｒｅｔｅｉｌ Ｖａｌ Ｄｅ Ｍａｒｎｅ フマレート−ｃｏ−放出分子ハイブリッド、炎症性疾患又は心血管疾患の治療におけるそれらの使用及びそれらの調製方法
BR112021020055A2 (pt) * 2019-04-12 2021-12-07 Mitobridge Inc Indutores de hmox1

Also Published As

Publication number Publication date
CA3127548A1 (fr) 2020-07-23
EP3911319A4 (fr) 2022-09-21
WO2020150306A1 (fr) 2020-07-23
US20210338644A1 (en) 2021-11-04
MX2021008071A (es) 2021-09-08
AU2020209144A1 (en) 2021-07-29
KR20210129034A (ko) 2021-10-27
CN113557019A (zh) 2021-10-26
JP2022517130A (ja) 2022-03-04

Similar Documents

Publication Publication Date Title
TW202334111A (zh) Tlr7/8拮抗劑之用途
US20070203153A1 (en) Compositions and methods for treating thrombocytopenia
WO2016089648A1 (fr) Inhibiteurs de bach1 en combinaison avec des activateurs de nrf2 et compositions pharmaceutiques les contenant
JP2019011343A (ja) 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤
BR112021000358A2 (pt) Uso de estimulantes de sgc para o tratamento de distúrbios mitocondriais
EP3145513A1 (fr) 3-(4-((4-(morpholinométhyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)pipéridine-2,6-dione pour le traitement du lupus érythémateux systémique
US20210338644A1 (en) Substituted Fused Imidazole Derivatives and Methods of Treating Sickle Cell Disease and Related Complications
IL291898A (en) Quinone-, hydroquinone-, and naphthoquinone- analogs of vetiquinone for the treatment of mitochondrial disorders
KR20160003652A (ko) 감마―글루타밀 주기 조절 방법 및 조성물
TW200927090A (en) Novel sulfamate compounds for medical use
KR20240051953A (ko) Pi3k 이소형 알파를 억제하는 화합물 및 암 치료 방법
CA3056873A1 (fr) Derives de sulindac aptes a proteger des cellules normales contre le stress oxydatif
WO2023272571A1 (fr) Utilisation médicale d&#39;un dérivé de 2,3-époxysuccinyle
US20050054714A1 (en) Nitric oxide releasing drugs for Alzheimer&#39;s disease
WO2014014698A2 (fr) Agonistes et antagonistes muscariniques bitopiques et procédés de synthèse et d&#39;utilisation associés
KR101898610B1 (ko) ＰＰＡＲδ 활성물질의 태자 재프로그래밍 용도
JP6381605B2 (ja) 脳卒中治療用のイリドイド配糖体類化合物、その医薬組成物及びその使用方法
TWI811901B (zh) 一種嘧啶甲醯胺類化合物及其應用
US20240216320A1 (en) Compositions and methods for treating sickle cell disease
WO2024061172A1 (fr) Inhibiteur de la prolyl hydroxylase et son utilisation
US20210145783A1 (en) Compositions and Methods for Treating Sickle Cell Disease
EP4337199A1 (fr) Méthodes de traitement de protoporphyrie érythropoïétique, de protoporphyrie liée à l&#39;x ou de porphyrie érythropoïétique congénitale avec des inhibiteurs de transport de glycine
EP4304597A1 (fr) Compositions et méthodes de traitement de l&#39;anémie associée à un trouble ribosomique
CN115429804A (zh) Ikzf1、ikzf3和btk多靶点调节剂的应用
WO2015095821A1 (fr) Composés épidithiodicétopipérazines, compositions et procédés

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210707

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ATTUCKS, OTIS CLINTON.

DAV Request for validation of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: ATTUCKS, OTIS CLINTON

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40060384

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20220823

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 7/00 20060101ALI20220817BHEP

Ipc: A61K 45/06 20060101ALI20220817BHEP

Ipc: A61K 31/4184 20060101ALI20220817BHEP

Ipc: A61K 31/225 20060101ALI20220817BHEP

Ipc: A61K 31/22 20060101ALI20220817BHEP

Ipc: A61K 31/17 20060101ALI20220817BHEP

Ipc: A61K 31/4188 20060101ALI20220817BHEP

Ipc: A61K 31/437 20060101ALI20220817BHEP

Ipc: A61K 31/428 20060101AFI20220817BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230510